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Organisms frequently make effort-related decisions in order to overcome obstacles
separating them from significant stimuli. Effort-related behavioral processes are an important
aspect of motivation, and effort-related motivational dysfunctions can be critical symptoms of
depression and other disorders. The current work explores the use of a novel operant task, the
concurrent progressive ratio (PROG)/chow feeding choice task. Rats tested on the PROG/chow
feeding task are given a choice between lever pressing on a progressive ratio for preferred food
pellets vs. approaching and consuming the less preferred lab chow that is concurrently available.
Experiments with this task included manipulations of DA systems including DA D1
antagonism, DA D2 antagonism and DA depletion (tetrabenazine (TBZ)). Manipulations that
interfere with DA transmission decreased total lever presses, maximum ratio achieved and active
lever time (i.e., time spent responding), but did not produce any decrease in chow consumption
on the PROG/chow. The CB1 inverse agonist AM251 decreased all measures including chow
consumption. The adenosine A2A antagonist MSX-3 increased lever pressing measures and
decreased chow intake. pDARPP-32(Thr34) was greater in nucleus accumbens core of high
responders (rats with high lever pressing output) compared to low responders. Additional studies
sought to assess the ability of putative or common antidepressants to reverse the effects of the
interference with DA transmission. The antidepressant bupropion, the A2A antagonist MSX-3

Patrick Arthur Randall – University of Connecticut, 2013
and the MAO-B inhibitor deprenyl all reversed the effects of TBZ on the PROG/chow
procedure.
Additional work assessed the Flinders Sensitive Line (FSL), using the PROG/chow
procedure and a variety of other behavioral tasks. FSL rats did not demonstrate clear effortrelated deficits compared to controls. Instead they showed broad impairments in appetite and
food motivation. Finally, this work assesses the effects of the common antidepressant bupropion
for its effects on PROG/chow performance. Bupropion increased extracellular DA and DArelated signal transduction activity and significantly increased responding on the PROG/chow
procedure. This effect was more pronounced in low performers compared to high performers.
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Introduction
Background: Behavioral Activation and Effort-related Aspects of Motivation
Motivated behavior involves a complex set of processes that regulate the probability,
proximity and availability of significant stimuli in an organisms’ environment. Furthermore,
motivated behavior has at least two important aspects; directional and activational. Directional
aspects refer to the fact that behavior is directed towards or away from significant stimuli.
Activational aspects refer to the fact that behavior also be characterized by high levels of
activity, vigor, or persistence, which enables organisms to overcome work-related response costs
to gain access to significant stimuli (Salamone, 1988; Salamone et al., 1991, 1997, 2007;
Salamone and Correa, 2002; Beeler et al., 2012; Mai et al., 2012).
Brain dopamine (DA), particularly in nucleus accumbens, plays an important role in
regulating these activational aspects of motivation. Several studies have demonstrated that
increased activity induced by scheduled presentation of food pellets is accompanied by increases
in accumbens DA release, and is reduced by DA antagonism and accumbens DA depletions
(Salamone 1986, 1988; McCullough and Salamone 1992). In addition, rats with accumbens DA
depletions are very sensitive to ratio requirements in operant schedules (Aberman and Salamone,
1999; Correa et al., 2002; Mingote et al., 2005). Moreover, DA antagonism or interference with
accumbens DA transmission alters response allocation in tasks that measure effort-related choice
behavior (Salamone et al., 1991, 1997, 2007, 2012), biasing animals towards the selection of low
effort alternatives to obtain reinforcers.
Effort-related decision making tasks offer animals a choice between the selection of high
effort instrumental behaviors that lead to more highly valued reinforcers, vs. low effort/low value
alternatives. Several behavioral tasks have been used to investigate the role of DA in effort-
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related choice. Some studies have used a T-maze barrier choice task in which a rat is given a
choice between climbing a barrier to gain access to an amount of a preferred food, or instead
approaching and consuming a smaller amount of the same food. These studies have reported that
interference with DA transmission decreased barrier climbing, shifting behavior towards the less
effortful option (Salamone et al., 1994; Cousins et al., 1996; Denk et al. 2005; Mott et al., 2009;
Pardo et al. 2012; Mai et al. 2012). Moreover, lever pressing versions of effort discounting
procedures also have demonstrated that DA antagonism shifts choice behavior of rats towards
low effort alternatives (Floresco et al. 2008; Bardgett et al. 2009).
Another task that has been used to examine effort-related choice behavior is the
concurrent fixed-ratio 5 (FR5)/chow feeding choice procedure. With this procedure, rats can
either lever press on a FR5 schedule for preferred high-carbohydrate food pellets, or approach
and consume less-preferred rodent chow that is freely available in the chamber (Salamone et al.,
1991, 2002, 2007). Under baseline conditions, rats tested with this procedure typically obtain
most of their food by lever pressing while consuming very little of the chow. Systemic or intraaccumbens administration of DA antagonists and accumbens DA depletions shift response
allocation such that lever pressing is decreased but chow intake is substantially increased
(Salamone et al., 1991, 1996, 2002; Cousins et al., 1993; Koch et al. 2000; Nowend et al. 2001;
Sink et al., 2008; Farrar et al., 2010). This effect is not due to drug-induced changes in food
preference or consumption (Salamone et al. 1991; Koch et al. 2000; Nunes et al. in preparation).
Moreover, the effects induced by DA antagonism or depletion differ substantially from those
seen following pre-feeding (Salamone et al., 1991) or treatment with appetite suppressant drugs
such as fenfluramine (Salamone et al., 2002) or cannabinoid CB1 antagonists (Sink et al., 2008);
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these appetite-related manipulations failed to increase chow intake at doses that suppress lever
pressing.
In addition to accumbens DA, there is a body of research implicating adenosine in
behavioral activation and effort-related processes (Farrar et al., 2007; Font et al., 2008; Mingote
et al., 2008). Adenosine A2A receptors are primarily localized in striatal areas, including both
neostriatum and accumbens (Schiffmann et al., 1991; Ferre et al., 2004). Furthermore, there is a
functional interaction between DA D2 and adenosine A2A receptors (Ferre, 1997; Hillion et al.,
2002; Fuxe et al., 2003). Intra-accumbens injections of the adenosine A2A agonist CGS 21680
decreased lever pressing on a ratio schedule (Mingote et al. 2008), and also produced changes in
effort-related choice behavior similar to the effects of DA antagonism (Font et al. 2008). In
contrast, adenosine A2A antagonists have been shown to increase fixed interval response rate
(Randall et al. 2011). Furthermore, several studies have shown that adenosine A2A antagonists
can reverse the effects of DA D2 antagonists on tests of effort-related choice behavior (Farrar et
al., 2007, 2010; Mott et al. 2009; Salamone et al., 2009; Nunes et al. 2010; Pardo et al. 2012).
Moreover, adenosine A2A antagonists have been shown to reverse the neurochemical effects of
DA D2 antagonism as measured by cFos and DARPP-32 immunoreactivity (Santerre et al.,
2012).

Clinical Significance of Motivational Dysfunction
Pathologies involving effort-related aspects of motivation are recognized as an important
feature of various psychiatric syndromes (Tylee et al., 1999; Stahl, 2002; Salamone et al., 2006;
Treadway and Zald, 2011). Clinicians have come to emphasize the importance of motivational
symptoms related to effort expenditure, such as psychomotor slowing, apathy, anergia, and
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fatigue, in major depression, parkinsonism, multiple sclerosis and other disorders (Tylee et al.
1999; Stahl 2002; Demyttenaere et al. 2005, Salamone et al. 2006; Treadway and Zald 2011).
The severity of psychomotor or energy-related symptoms in depression is related to problems
with social function, employment and treatment outcomes (Tylee et al. 1999; Stahl 2002).
Moreover, it has been argued that many people with major depression have fundamental deficits
in reward seeking, exertion of effort, and effort-related decision making that do not simply
depend upon problems that they may have experiencing pleasure (Treadway and Zald 2011).
A task similar to the concurrent lever pressing/choice tasks used in our lab has been
developed for use in humans. The “Effort Expenditure for Rewards Task (EEfRT) developed by
Treadway and colleagues (2009) gives a human subject a choice between an easy or difficult
button pressing task for a chance to win differential monetary rewards based on task difficulty
and probability of reinforcement. Wardle et al. (2011) found that when normal subjects are
administered amphetamine prior to a testing session, they are more likely to choose the harder
task and work for a larger reward, even if the probability of reinforcement is very low. Treadway
et al. (2012a) further demonstrated that individual differences in striatal DA transmission were
correlated with willingness to exert effort for larger rewards, in particular when reward
probability was low. In contrast, when depressed patients are tested on this task, they show less
willingness to exert effort for larger rewards, even when reward probability is high (Treadway et
al., 2012b). Using a similar task, Gold et al. (2013) demonstrated that schizophrenic patients
with a preponderance of negative symptoms also showed alterations in effort-related decision
making, showing less willingness to select high effort options in the choice task.
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Animal Studies of Effort-Related Choice: Potential as Models of Motivational Symptoms
Recent studies have focused on the ability of several different manipulations associated
with depression to produce alterations in effort-related choice behavior (Nunes et al. 2013;
Nunes et al. submitted). Several experiments examined the effects of tetrabenazine (TBZ), the
selective vesicular monoamine transporter-2 (VMAT-2) inhibitor, on effort-related choice tasks.
By inhibiting vesicular storage, TBZ acts to deplete DA and NE with its greatest effects in DA
terminals in striatal areas (Pettibone et al., 1984). The effects of TBZ have considerable clinical
significance, because TBZ is already prescribed to treat hyperkinetic disorders including
Huntington’s disease, but patients demonstrate side effects such as fatigue, anergia and
depression following treatment with TBZ (Frank, 2009, 2010; Guay, 2010). Moreover, VMAT-2
has been used as a “gold standard” for marking DA terminals in both primates and rats (Wang et
al., 2010; Boileau et al., 2010). When TBZ is administered on the FR5/choice task, rats shift their
behavior away from lever pressing to chow consumption, similar to DA antagonism (Nunes et
al., submitted). Furthermore, these effects can be reversed by both adenosine A2A antagonism
and the widely used antidepressant bupropion (Nunes et al., submitted). In-vivo microdialysis
studies support these findings, demonstrating significant decreases in extracellular DA in
accumbens core following administration of TBZ (Nunes et al., submitted).
In addition to pharmacological manipulations that induce depression-like symptoms, it is
also possible to model some of these symptoms using selective breeding procedures. One such
example is the Flinders Sensitive line (FSL). This line was originally bred with the goal of
developing a model of anticholinesterase resistance for pesticide research (Overstreet et al.,
1979), but as it turned out these rats showed an enhanced sensitivity to cholinergic stimulation
that would prove useless for pesticide research. It was the work of Janowski et al. (1980) that
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brought the study of FSL rats into the depression field. They noted that patients diagnosed as
clinically depressed similarly demonstrate a higher sensitivity to cholinergic stimulation than
non-depressed controls. In the years that followed, numerous groups began breeding using the
FSL rats as a screening tool for different measures of depression-like behavior and subsequent
antidepressant interventions (Overstreet et al., 2005, 2013). For example, these rats show
decreased swim time compared to controls on the forced swim test, an effect that is reduced with
administration of 5-HT uptake inhibitors (Overstreet, 1993).
FSL rats have been studied on a multitude of behavioral paradigms related to aspects of
depression, however, they have yet to be assessed on measures of effort-related choice. There is
evidence of psychomotor slowing in FSL rats as shown through basic operant tasks (Overstreet
and Russel, 1982; Bushnell et al., 1995). Moreover, there is evidence for 5-HT “subsensitivity”
leading to decreased DA release in nucleus accumbens in FSL rats (Zangen et al., 2001).
Furthermore, when FSL rats were given chronic treatment with a 5-HT uptake inhibitor such as
fluoxetine, accumbens DA transmission is restored to control levels (Yadid et al., 2000; Zangen
et al., 2001; Dremencov et al., 2004). Moreover, there is evidence that FSL rats are less prone to
developing stereotypy following administration of high doses of amphetamine compared to
controls. Crocker and Overstreet (1991) observed similar effects following DA antagonism or
neostriatal DA depletion. Taken together, these studies suggest that there may be an impairment
in DA transmission in FSL rats that may lead to effort-related impairments that could be assessed
using effort-related choice tasks.
In addition to modeling the effort-related effects of conditions associated with depression,
there is a necessary focus on assessing treatments for depression in animal models. Due to the
heterogeneous nature of depression, it makes it very difficult to effectively treat all patients;
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some patients have severe psychomotor retardation and anergia, while others may have a
different constellation of symptoms (Tylee et al., 1999; Stahl, 2002). It is estimated that between
33% and 57% of depressed patients suffer from treatment-resistant depression (Lum and Stahl,
2012), not responding to any of the available treatments. Moreover, for many patients, there is
considerable lag time between beginning treatment and report of improvement of symptoms
(Willner, 1997; Treadway and Zald, 2011). For these reasons, researchers are regularly seeking
novel treatments for depressed patients.
Although many immediately associate depression with serotonin, several studies suggest
that DA-related treatments such as bupropion (Wellbutrin) are as effective as SSRI’s in treating
major depression, regardless of anxiety baseline (Thase et al., 2005; Trivedi et al., 2001; Rush et
al., 2001a, 2001b). Furthermore, bupropion has been demonstrated to be more effective in
treating the effort-related motivational symptoms of depression compared to SSRI’s (Papakostas
et al., 2006). Moreover, fewer patients experienced fatigue or sleepiness when coming off of
bupropion compared to SSRI’s (Papakostas et al., 2006). Animal studies with bupropion
demonstrate its ability to reverse the effort-related impairments produced by TBZ on both the
FR5/chow task (Nunes et al., 2013, submitted) and the T-Maze barrier task (Yohn et al., 2013,
IN PREP).
Another group of potential candidates that have resurfaced recently for the treatment of
depression are compounds that inhibit catechol-o-methyltransferase (COMT) (Fava et al., 1999).
COMT is an enzyme that catalyzes the methylation and resulting breakdown of DA and NE.
Importantly, there is evidence that COMT levels are increased in depressed patients compared to
non-depressed controls (Shulman et al., 1978). Moreover, drugs that inhibit COMT have been
used effectively to increase the bioavailability of L-DOPA in Parkinson’s patients (Moreau et al.,
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1994, Muller et al., 2009). Futhermore, parkinsonian patients undergoing treatment with the
COMT inhibitor entacapone in addition to L-DOPA and carbidopa report significant
improvements in rates of depression, compared to patients treated with L-DOPA and carbidopa
alone (Fung et al., 2009). In addition, animal studies of the COMT inhibitor tolcapone have
shown increases in CNS levels of S-adenosyl-L-methionine (SAMe), a compound shown to have
antidepressant effects in humans (Bressa, 1994). Furthermore, it has been hypothesized that
tolcapone could be efficacious for treating depression if used in combination with other DA
promoting agents such as D1 agonists or DA uptake inhibitors like bupropion (Willner, 1997).
Moreover, a clinical study reported that tolcapone significantly improved symptoms in patients
with major depression (Fava et al. 1999). In addition, genetic variations in the COMT gene in
humans result in changes in enzyme activity that are associated with the susceptibility for
manifesting depressive symptoms, including lower motivation (Aberg et al. 2011).
Another target for potential antidepressants are drugs that block monoamine oxidase
(MAO). MAO is an enzyme found on the mitochondrial surface within terminals and similar to
COMT, is in part responsible for the break down and metabolism of monoamines including DA.
For this reason there has been interest in the ability of MAO inhibitors (MAO-Is) to decrease
depressive symptoms. The MAO-I deprenyl has been shown to have antidepressant effects on
several of the traditional animal models of depressive behavior including the forced swim test
and inescapable shock paradigm (Martin et al., 1987, Shulz et al., 2010). Furthermore, deprenyl
has been shown to increase locomotion in animals treated with a combined carbidopa/L-DOPA
cocktail, similar to tolcapone (Mercuri et al., 1999).
As described above, adenosine A2A antagonists have been reported to reverse the effects
of DA D2 antagonists on effort-related choice behavior (Farrar et al. 2007, 2010; Salamone et al.
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2009; Mott et al. 2009; Worden et al. 2009; Nunes et al. 2010; Santerrre et al. 2012). Based
upon these findings, it has been suggested that adenosine A2A antagonists could be useful as
treatments for the effort-related symptoms of depression (Salamone et al. 2007). This suggestion
is consistent with research indicating that adenosine A2A antagonists show antidepressant-like
effects in traditional animal models of depression, such as the tail suspension and forced swim
tests (Hodgson et al. 2009; Hanff et al. 2010).

Current Studies
The current work was conducted with several goals in mind. The first set of experiments
were undertaken to characterize the development of a novel lever pressing procedure
(PROG/chow) for measuring the impact of DA-related manipulations on effort-related decision
making. The PROG/chow procedure is a variant of the FR5/chow procedure referenced above.
With this procedure, rats have a choice between responding on a progressive ratio schedule to
receive preferred Bio-serve pellets or instead, approaching and consuming freely available lab
chow. An advantage of this procedure is that it produces a wider range of performance (i.e., high
performers who lever press and eat very little chow and low responders who respond very little
and eat more chow). This range of performance allows for a more in depth analysis of the
behavior. Moreover, because baseline chow consumption on the PROG/Chow procedure is
considerably higher than the FR5/Chow procedure, it allows for observable decreases in chow
consumption with appetite manipulations.
The first set of studies (chapter 2) examined the effects of several manipulations designed
to demonstrate the difference between effort-related effects and appetite-related effects on the
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PROG/chow procedure. For these studies, the DA D2 antagonist haloperidol, the adenosine A2A
antagonist MSX-3, the effects of pre-feeding to reduce food motivation, and the effects of the
cannabinoid CB1 antagonist and putative appetite suppressant AM251 were studied. In addition,
DARPP-32-THR34 immunoreactivity was measured in order to better understand differences in
DA-related signal transduction activity that are seen between high performers and low
performers on this task.
The second group of experiments (chapter 3) was designed to expand on the earlier work
with the PROG/chow procedure. For these experiments, we examined the effects of both DA D1
and D2 antagonism and compared that to the effects of DA depletion with TBZ. In addition, the
ability of several common and putative antidepressant compounds were assessed for the ability
to reverse the impairments induced by TBZ. Furthermore, the cannabinoid CB1 antagonist and
putative appetite suppressant AM4113 was used to serve as a contrast to the effects of DA
manipulations. Finally, the ability of putative and well known antidepressants, including the
adenosine A2A antagonist MSX-3, the DA uptake inhibitor bupropion, the MAO-I deprenyl and
the COMT inhibitor tolcapone, were all studied.
The third group of experiments (chapter 4) focuses on work with FSL rats with the goal
of assessing their utility as a model of the effort-related symptoms of depression. These rats,
along with normal Sprague-Dawley controls were trained on the PROG/chow feeding choice
task as well as several other task related to operant response output, measures of anxiety (open
field, elevated plus maze), and free-feeding to assess differences in food consumption and
preference.
The final group of experiments (chapter 5) focuses on the catecholamine uptake inhibitor
and common antidepressant bupropion. These studies took both a behavioral and neurochemical
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approach to characterize the effects of bupropion on effort expenditure and effort-related
decision making. The first experiment in this group assesses the ability of bupropion to increase
PROG/chow responding when administered alone. Furthermore, the differential effects of
bupropion on high responders versus low responders were assessed. The next set of experiments
sought to explain these effects using analysis of DARPP-32 (THR34 and THR75)
immunofluorescence following administration of bupropion in untrained animals, in order to
obtain measures of DA-related signal transduction in cAMP/protein kinase A cascades. The final
experiment in this group utilized in-vivo microdialysis to measure extracellular changes in
accumbens DA levels following administration of bupropion in untrained animals.
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Chapter 2: Dopaminergic modulation of effort-related choice behavior as assessed by a
progressive ratio chow feeding choice task: Pharmacological studies and the role of
individual differences

The following work is already published – Randall et al., 2012

Introduction
Brain dopamine (DA), particularly in nucleus accumbens, plays an important role in
regulating activational aspects of motivation (e.g. vigor, persistence), and enabling organisms to
overcome work-related response costs to gain access to significant stimuli (Salamone, 1988;
Salamone et al., 1991, 1997, 2007; Salamone and Correa, 2002; Beeler et al., 2012; Mai et al.,
2012). The increased activity induced by scheduled presentation of food pellets is accompanied
by increases in accumbens DA release, and is reduced by DA antagonism and accumbens DA
depletions (Salamone 1986, 1988; McCullough and Salamone 1992). Rats with accumbens DA
depletions are very sensitive to ratio requirements in operant schedules (Aberman and Salamone,
1999; Correa et al., 2002; Mingote et al., 2005). Moreover, DA antagonism or interference with
accumbens DA transmission alters response allocation in tasks that measure effort-related choice
behavior (Salamone et al., 1991, 1997, 2007, 2012).
Several behavioral tasks have been used to investigate the role of DA in effort-related
choice. Some studies have used a T-maze barrier choice task, and reported that interference with
DA transmission decreased barrier climbing to gain access to a high magnitude of reinforcement
(Salamone et al., 1994; Cousins et al., 1996; Denk et al. 2005; Mott et al., 2009; Pardo et al.
2012; Mai et al. 2012). T-maze and lever pressing versions of effort discounting procedures also
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have demonstrated that DA antagonism shifts choice behavior of rats towards low effort
alternatives (Floresco et al. 2008; Bardgett et al. 2009). Another task that has been used is the
concurrent fixed-ratio 5 (FR5)/chow feeding procedure, in which rats can either lever press on a
FR5 schedule for preferred high-carbohydrate food pellets, or approach and consume lesspreferred rodent chow that is freely available in the chamber (Salamone et al., 1991, 2002, 2007).
Under baseline conditions, rats tested with this procedure typically obtain most of their food by
lever pressing while consuming very little of the chow. Systemic or intra-accumbens
administration of DA antagonists and accumbens DA depletions shift response allocation such
that lever pressing is decreased but chow intake is substantially increased (Salamone et al., 1991,
1996, 2002; Cousins et al., 1993; Koch et al. 2000; Nowend et al. 2001; Sink et al., 2008; Farrar
et al., 2010). This effect is not due to drug-induced changes in food preference or consumption
(Salamone et al. 1991; Koch et al. 2000). Moreover, the effects induced by DA antagonism or
depletion differ substantially from those seen following pre-feeding (Salamone et al., 1991) or
treatment with appetite suppressant drugs such as fenfluramine (Salamone et al., 2002) or
cannabinoid CB1 antagonism (Sink et al., 2008); these appetite-related manipulations failed to
increase chow intake at doses that suppress lever pressing.
In addition to accumbens DA, there is a body of research implicating adenosine in
behavioral activation and effort-related processes (Farrar et al., 2007; Font et al., 2008; Mingote
et al., 2008). Adenosine A2A receptors are primarily localized in striatal areas, including both
neostriatum and accumbens (Schiffmann et al., 1991; Ferre et al., 2004). Furthermore, there is a
functional interaction between DA D2 and adenosine A2A receptors (Ferre, 1997; Hillion et al.,
2002; Fuxe et al., 2003). Intra-accumbens injections of the adenosine A2A agonist CGS 21680
decreased lever pressing on a ratio schedule (Mingote et al. 2008), and also produced changes in
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effort-related choice behavior similar to the effects of DA antagonism (Font et al. 2008). In
contrast, adenosine A2A antagonists have been shown to increase fixed interval response rate
(Randall et al. 2011). Furthermore, several studies have shown that adenosine A2A antagonists
can reverse the effects of DA D2 antagonists on tests of effort-related choice behavior (Farrar et
al., 2007, 2010; Mott et al. 2009; Salamone et al., 2009; Nunes et al. 2010; Pardo et al. 2012).
The present studies were undertaken to investigate a novel variant of the operant choice
procedure that utilizes a progressive ratio (PROG) work requirement (see also Schweimer and
Hauber, 2005). Similar to the FR5/chow feeding choice task, rats tested with this PROG/chow
feeding procedure have the choice of pressing the lever reinforced by presentation of the more
preferred pellets vs. approaching and consuming the less preferred chow; the difference is that a
PROG schedule, which gradually increases the ratio requirement, is used instead of an FR5. To
assess the effects of DA antagonism and compare these actions with other conditions,
experiments were conducted to determine the effects of the DA D2 antagonist haloperidol, the
adenosine A2A antagonist MSX-3, the cannabinoid CB1 antagonist/inverse agonist and putative
appetite suppressant AM251, and the reinforcer devaluation provided by pre-feeding.
Furthermore, to investigate signal transduction activity that is potentially related to task
performance, expression of DARPP-32 that is phosphorylated at the threonine 34 residue
(pDARPP-32-(Thr34); Segovia et al., 2012) was measured immunohistochemically in 4 specific
regions of interest. This experiment was conducted to determine if levels of pDARPP-32(Thr34)
expression were higher in animals with high lever pressing output. Nucleus accumbens is
implicated in effort-related processes, so both the core and shell divisions were analyzed for
pDARPP-32(Thr34) activity following a PROG/chow behavioral session. Because Schweimer
and Hauber (2005) demonstrated the importance of DA signaling in the anterior cingulate cortex
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in effort-related decision making, CG1 and CG2 divisions of the cingulate cortex also were
analyzed.
It was hypothesized that haloperidol would affect PROG responding in a manner that was
not dependent upon decreases in primary food motivation or appetite, and thus would decrease
PROG lever pressing but leave chow intake intact. Moreover, it was hypothesized that MSX-3
would produce behavioral effects that would be opposite to those produced by haloperidol. Due
to the putative appetite suppressant effects of interfering with cannabinoid CB1 receptor
transmission (McLaughlin et al. 2003; Salamone et al. 2007; Sink et al. 2008; Randall et al.
2010), it was expected that AM251, as well as pre-feeding, would decrease both lever pressing
and chow consumption. Finally, it was hypothesized that accumbens DARPP-32
immunoreactivity would be greater in animals with high baseline levels of lever pressing (i.e.,
“high responders”) than in rats with low levels of lever pressing.
Materials and Methods:
Animals:
48 adult male Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) were housed in a
colony at 23 °C with 12-h light/dark cycles (lights on at 0:700 h). Rats weighed 300–350 g at the
beginning of the study, and were initially food deprived to 85% of their free-feeding body weight
for training. Rats were fed supplemental chow to maintain weight throughout the study, with
water available ad libitum in the home cages. Despite food restriction, rats were allowed modest
weight gain throughout the experiment. All animal protocols were approved by the University of
Connecticut Institutional Animal Care and Use Committee, and followed NIH guidelines.
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Pharmacological Agents and Dose Selection:
Haloperidol was obtained from Sigma-Aldrich (St. Louis, MO) and was dissolved in
0.2% tartaric acid solution. MSX-3 ((E)-phosphoric acid mono-[3-[8-[2-(3methoxyphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl] propyl]
ester disodium salt) was synthesized in the laboratory of Christa Müller (University of Bonn,
Bonn, Germany). MSX-3 was dissolved in 0.9% saline and pH adjusted with 1.0M NaOH to a
final pH of 7.4. AM251 was synthesized in the laboratory of Alex Makriyannis (Center for Drug
Discovery, Northeastern University, Boston, MA). AM251 was dissolved in dimethylsulfoxide
(DMSO), Tween 80, and 0.9% saline at a ratio of 1:1:8. Doses were selected based on previous
work (Sink et al., 2008; Salamone et al., 2009; Randall et al., 2011).

Behavioral Procedures:
Preliminary studies were conducted to determine the optimal rate at which the schedule
progressed (i.e., number of reinforcements per ratio level and by how much the ratio requirement
increased with each level). It was found that by having to complete 15 ratios at each ratio level,
rats generally lever pressed at higher levels before switching to chow. Behavioral sessions were
conducted in operant conditioning chambers (28x23x23 cm3; Med Associates). Rats were
initially trained to lever press on a continuous reinforcement schedule (30-min sessions; 45-mg
pellets, Bioserve, Frenchtown, NJ, USA) for 1 week, and then were shifted to the PROG
schedule (30-min sessions, 5 days/week) for several additional weeks. For PROG sessions, the
ratio started at FR1 and was increased by one additional response every time 15 reinforcements
were obtained (FR1x15, FR2x15, FR3x15,…). Additionally, this schedule included a “time-out”
feature that deactivated the response lever if 2 minutes elapsed without a ratio being completed.
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Upon reaching stable baseline responding, chow was then introduced. Weighed amounts of
laboratory chow (Laboratory Diet, 5P00 Prolab RMH 3000, Purina Mills, St. Louis, MO, USA;
typically 15–20 g) were concurrently available on the floor of the chamber during the PROG
sessions. At the end of the session, rats were removed from the chamber, and food intake was
determined by weighing the remaining food (including spillage). Rats were trained until they
attained stable levels of baseline lever pressing and chow intake, after which drug testing began.
For most baseline days rats did not receive supplemental feeding, however, over weekends and
after drug tests, rats received supplemental chow in the home cage. On baseline and drug
treatment days, rats normally consumed all the operant pellets that were delivered during each
session.

Experimental Procedures:
For experiments 1-3a and 4, the same group of animals was used (n=32), while a
different group of animals was used for experiment 3b (n=16). For all experiments using drug
manipulations (1,2,3b), all animals were given a single vehicle injection 1 week prior to the
beginning of testing to habituate them to being injected. Experiments 1,2, and 3b used a withingroup design in which each rat received all drug or vehicle treatments (IP) in their particular
experiment in a randomly varied order (one treatment per week). Baseline training sessions (i.e.,
non-drug) were conducted 4 days per week.
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Experiment 1: Effects of the dopamine D2 antagonist haloperidol on PROG/chow feeding choice
performance.
To assess the effects of haloperidol, rats were trained on the PROG/chow procedure
described above. On test days, animals received injections of 0.025, 0.05, 0.1 mg/kg haloperidol
or vehicle, 50 minutes prior to behavioral testing.

Experiment 2: Effects of the adenosine A2A antagonist MSX-3 on PROG/chow feeding choice
performance.
To assess the effects of the adenosine A2A antagonist MSX-3, the same group of animals
was used. The animals were first given 1 week off from any drug testing, but continued normal
baseline training. On test days, animals received injections of 0.5, 1.0, 2.0 mg/kg MSX-3 or
vehicle, 20 minutes prior to behavioral testing.

Experiment 3a/b: Effects of appetite manipulations on PROG/chow performance.
3a. Effects of pre-feeding to reduce food motivation
To assess the effects of pre-feeding, the same group of animals was again given 1 week
of additional baseline training after experiment 2. The night before testing, animals were taken
off of food restriction and given ad libitum access to lab chow. On the test day, several hours
before behavioral testing, animals were given ad libitum access to Bioserve pellets in the home
cage. Performance on the test day was then compared to performance on the previous baseline
day.
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3b: Effects of the cannabinoid CB1 inverse agonist and putative appetite suppressant AM251
To assess the effect of AM251, a new group of animals (n=16) were trained on the
PROG/chow feeding choice procedure described above. On test days, animals received
injections of 2.0, 4.0, 8.0 mg/kg AM251 or vehicle, 30 minutes prior to testing, once per week, in
a randomly varied order.

Experiment 4: Effects of PROG/chow responding on pDARPP32-THR34 expression: high vs.
low responders.
Following the conclusion of experiment 3, animals (n=32) were given 1 week to restabilize their baselines. During the following week, 90 minutes after a baseline training session,
animals were sacrificed and perfused to obtain tissue for pDARPP32-(Thr34)
immunohistochemical analysis. For statistical analysis, these animals were divided into two
groups (high performers and low performers, determined by a median split of lever pressing on
the day of perfusion).

pDARPP32(Thr34) visualization and quantification:
Free floating coronal sections (50µm) were serially cut using a cryostat (Weymouth, MA,
USA) and rinsed in 0.01M PBS (pH 7.4). pDARPP32-(Thr34) immunohistochemistry was
conducted according to the methods described previously by Segovia et al. (2012). The primary
anti-pDARPP32-(Thr34) antibody was used at a concentration of 1:1000 (Santa Cruz
Biotechnology, USA) for 48 h incubation, and the secondary antibody was anti-rabbit HRP
conjugate, envision plus (DAKO, Carpinteria, CA, USA). The immunohistochemical reaction
was developed using diaminobenzidine (DAB) as the chromagen. The mounted and cover-
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slipped sections were examined and photographed using a Nikon Eclipse E600 (Melville, NY,
USA) microscope equipped with an Insight Spot digital camera (Diagnostic Instruments, Inc).
Images of the regions of interest were magnified at 20x and captured digitally using SPOT
software. Cells that were positively labeled for pDARPP32-(Thr 34) were quantified with
ImageJ software (v. 1.42, National Institutes of Health sponsored image analysis program) and a
macro written to automate particle counting with regions of interest (1000x1000µm; see figure
5). For each animal, cell counts were obtained bilaterally from at least three sections, and counts
were averaged across sides and sections. All cell counting was done by someone who was blind
to the experimental conditions.

Statistical Analysis:
For the behavioral pharmacology experiments, number of lever presses, maximum ratio
achieved, active lever time (in seconds) and chow intake (grams) were analyzed using repeated
measures analysis of variance (ANOVA). Non-orthogonal planned comparisons using the
ANOVA error term (Keppel, 1991) were used to compare each treatment with the vehicle
control. In addition, to provide another statistical measure of the reciprocal relationship between
lever pressing and chow intake in each experiment, correlations were performed between number
of lever presses and chow intake data collapsed across all conditions within the experiment (e.g.,
Salamone et al. 2002). For experiment 4, pDARPP32-(Thr34) cell counts were analyzed for
differences in expression between high and low responders (after a median split of the lever
pressing data) for each of 4 regions of interest, and t-tests were performed to determine
significant differences.
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Results:
Experiment 1 – Effects of the DA D2 antagonist haloperidol
Haloperidol significantly decreased the number of lever presses (F(3,93) = 4.598, p <
0.01, see figure 1A). Planned comparisons revealed that there was a significant difference
between 0.1 mg/kg haloperidol and vehicle (p < 0.05). Haloperidol also significantly decreased
maximum ratio achieved (F(3,93) = 8.661, p < 0.01, figure 1B), and the amount of time the lever
remained active (F(3,93) = 6.723, p < 0.01, figure 1C); for both measures, planned comparisons
showed a significant difference between vehicle and 0.1 mg/kg haloperidol (p < 0.05).
Haloperidol produced no significant effects on chow consumption in the dose range tested
(figure 1D). However, there was a tendency for animals that had high vehicle rates of
responding, and correspondingly low vehicle levels of chow intake, to show increases in chow
intake with haloperidol; this was marked by the significant correlation between vehicle number
of lever presses and the difference in chow consumption between vehicle and the highest dose of
haloperidol (r = 0.69, df = 30, p < 0.05). Collapsed across all conditions, there was a significant
negative correlation between number of lever presses and chow consumption (r = -0.765, df =
126, p < 0.05), which demonstrated the overall inverse relationship between lever pressing and
chow intake.

Experiment 2 – Effects of the adenosine A2A antagonist MSX-3
MSX-3 significantly increased number of lever presses (F(3,93) = 4.120, p < 0.01, figure
2A), and planned comparisons showed that both 1.0 and 2.0 mg/kg doses of MSX-3 increased
number of lever presses compared to vehicle (p < 0.05). There also was a significant increase in
maximum ratio achieved (F(3,93) = 8.206, p < 0.01, see figure 2B), with the 1.0 and 2.0 mg/kg
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doses of MSX-3 differing significantly from vehicle (p < 0.05). Furthermore, MSX-3 increased
active lever time (F(3,93) = 3.784, p < 0.05, figure 2C), with the 2.0 mg/kg does of MSX-3 being
significantly affected (p < 0.05). MSX-3 decreased chow intake (F(3,93) = 8.017, p < 0.01;
figure 2D), with a significant effect at 2.0 mg/kg MSX-3 compared to vehicle (p < 0.05). As
with experiment 1, there was a significant negative correlation between lever presses and chow
intake when the data were collapsed across all conditions (r = -0.781, df = 126, p < 0.05).

Experiment 3 – Effects of appetite-related manipulations on PROG/chow performance: effects of
pre-feeding and the putative appetite suppressant AM251
Experiment 3a studied the effects of pre-feeding on PROG/chow intake choice
performance (Table 1). Compared to the previous baseline day, pre-feeding the animals prior to
the session produced marked decreases in number of lever presses (t = 2.96, df = 31, p < 0.05),
and maximum ratio achieved (t = 3.94, df = 31, p < 0.05), but no significant effect on active
lever time. Pre-feeding significantly decreased chow intake (t = 13.69, df = 31, p < 0.01)
compared to previous day baseline performance. There was no significant overall correlation
between number of lever presses and chow consumption (r = 0.12, df = 62, n.s.). Experiment 3b
studied the effects of the cannabinoid CB1 inverse agonist AM251. AM251 decreased the
number of lever presses (F(3,45) = 3.891, p < 0.05, figure 3A), and the maximum ratio achieved
(F(3,45) = 5.811, p < 0.05, see figure 3B). Planned comparisons showed that with both measures,
only the highest dose of 8.0 mg/kg AM251 significantly differed from vehicle (p < 0.05).
AM251 did not produce any significant changes in active lever time (figure 3C), but it
significantly decrease chow intake (F(3,45) = 45.634, p < 0.01, figure 3D), with all doses
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differing from vehicle (p < 0.05). There was no significant overall correlation between number of
lever presses and chow consumption (r = -0.05, df = 62, n.s.).

Experiment 4 - pDARPP-32(Thr34) Immunohistochemistry in high and low responders
Performance on the PROG/chow feeding choice task was highly variable; some rats lever
pressed fewer than 100 times and had high levels of chow intake, while others lever pressed
more than 1000 times and consumed small amounts of chow. This variability was seen across all
the experiments described above, and in some cases was related to the drug effects seen. For
example, the effects of haloperidol were more marked in rats with higher control levels of lever
pressing. When a median split was done, and high and low lever pressing was used as a factor in
a 2 x 4 factorial ANOVA, there was an overall effect of dose (F[3,90] = 5.071, p < 0.05) and
importantly, a dose by group interaction (F[3,90] = 4.189, p < 0.05). Although the repeated
measures ANOVA demonstrated that both low and high responders showed significant decreases
in number of lever presses (low responders: F(3,45) = 2.790, p < 0.05; high responders: F(3,45)
= 4.638, p < 0.05), analysis of effect sizes showed that the suppressive effect of haloperidol on
number of lever presses was greater in high responders (eta2 = 0.236) than low responders (eta2 =
0.157). Similar analyses revealed differences between high and low responders in the AM251
experiment, with only the high responders showing a significant drug effect on number of lever
presses. Because of this large variability, the final experiment investigated potential
neurochemical differences between high and low responders, using pDARPP-32(Thr34) as a
marker of signal transduction activity. To analyze the pDARPP-32(Thr34) expression data, a
median split based upon behavioral performance during the final test day was performed,
yielding two groups: high responders (n = 16, mean = 812.44, SEM = 201.68, range = 205–
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2852) and low responders (n = 16, mean = 116.31, SEM = 12.81, range = 54–190). Four regions
of interest were selected for analysis: cingulate cortex CG1/CG2 and accumbens core/shell
(Figures 4-5). There were no differences in pDARPP-32(Thr34) expression between high and
low responders in CG1 (t = -0.066, df = 28, n.s.) or CG2 (t = 0.172, df = 25, n.s.). Nucleus
accumbens shell showed no significant differences in pDARPP-32(Thr34) expression between
high and low responders (t = 1.415, df = 30, n.s.), but nucleus accumbens core showed a
significant difference in expression between high and low responders (t = 2.703, df = 29, p <
0.05, Figures 4-5).
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Table 1. Results of the pre-feeding experiment (Mean + SEM
of each behavioral measure).
Total Lever Presses

Maximum Ratio Achieved

Active Lever Time (sec)

Chow Consumption (g)

Baseline

Pre-Fed

468.97

107.53 *

+122.96

+10.78

6.66

3.63 *

+0.77

+0.20

736

584.75

+85.36

+34.77

6.77

0.58 *

+0.47

+0.12

* p < 0.05 different from baseline
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Figure 1: Effects of the dopamine D2 antagonist haloperidol on PROG/chow performance. On
measures of lever pressing, mean (+SEM) total lever presses (A), maximum ratio achieved (B),
and active lever time (measured in seconds, C), haloperidol significantly decreased at the highest
dose of 0.1 mg/kg. Chow consumption (mean +SEM, in grams) during test sessions was
unaffected by any dose tested (D). (* p < 0.05, different from vehicle).
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Figure 2: Effects of the adenosine A2A antagonist MSX-3 on PROG/chow performance. On
measures of lever pressing, mean (+SEM) total lever presses (A) and maximum ratio achieved
(B) were both significantly increased at doses of 1.0 and 2.0 mg/kg while active lever time
(measured in seconds, C) was only increased at a dose of 2.0 mg/kg. Chow consumption (mean
+SEM, in grams) during test sessions was significantly decreased at the dose of 2.0 mg/kg (D).
(* p < 0.05, different from vehicle) .
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Figure 3: Effects of the cannabinoid CB1 inverse agonist AM251 on PROG/chow performance.
On measures of lever pressing, mean (+SEM) total lever presses (A) and maximum ratio
achieved (B) were significantly decreased at 8.0 mg/kg while active lever time (measured in
seconds, C) was unaffected at any dose tested. Chow consumption (mean +SEM, in grams)
during test sessions was significantly decreased at 2.0, 4.0 and 8.0 mg/kg doses (D). (* p < 0.05,
different from vehicle).
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Figure 4: pDARPP-32(Thr34) immunocytochemistry – (A and B) Atlas plates (modified from
Paxinos and Watson, 1998) with regions of interest denoted by squares. (C) High magnification
photomicrograph of pDARPP-32(Thr34) immunoreactive cells at 40x magnification. Several
pDARPP-32(Thr34) positive cells are shown, including a darkly staining cell, with clear soma
and dendritic processes (arrow) (D) Mean (+SEM) number of pDARPP-32(Thr34) positive cells
counted in each region of interest in high performers and low performers. There were
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significantly more pDARPP-32(Thr34) positive cells counted in the nucleus accumbens core of
high performers compared to low performers. (* p < 0.05)

Figure 5: Photomicrographs of pDARPP-32(Thr34) staining in each region of interest, showing
representative low performers (left column) and high performers (right column). All images were
taken at 10X magnification.
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Chapter 3: Effects of TBZ on the PROG/Chow Procedure: Studies using well known and
putative antidepressants
Introduction:
Motivation is a complex process that involves multiple behavioral functions and neural
circuits (Salamone and Correa 2002, 2012; Berridge and Robinson 2003). Organisms are
directed towards or away from stimuli, they can respond to primary motivational stimuli and
conditioned cues, and under some conditions they can demonstrate high levels of behavioral
activation (Salamone et al. 2007; Everitt and Robbins 2007; Nicola 2010; Salamone and Correa
2012; McGinty et al. 2013). One of the manifestations of activational aspects of motivation is
that organisms can show robust activity in the initiation and maintenance of motivated behavior,
leading to substantial and persistent work output in their instrumental (i.e., reinforcer-seeking)
actions. Thus, organisms can overcome response costs separating them from motivational
stimuli, and frequently they must make effort-related decisions based upon cost/benefit analyses
(Salamone and Correa 2002, 2012). In the last few years, there has been growing interest in the
neural circuitry underlying effort-based processes, both in animals (Salamone et al. 1997, 2007;
Walton et al. 2003; Floresco et al., 2008; Mingote et al. 2008; Hauber and Sommer 2009;
Salamone and Correa 2012) and humans (Croxson et al. 2009; Botvinick et al. 2009; Kurniawan
et al. 2010; Wardle et al. 2011; Treadway et al. 2012a). These studies indicate that the forebrain
circuits regulating exertion of effort and effort-related choice behavior involve several structures,
including basolateral amygdala and prefrontal/anterior cingulate cortex (Walton et al. 2003;
Floresco and Ghods-Sharifi 2007; Hauber and Sommer 2009), ventral pallidum (Mingote et al.
2008; Farrar et al. 2008), and nucleus accumbens (Salamone et al. 1994, 2007; Font et al. 2008;
Farrar et al. 2010; Mai et al. 2012; Nunes et al. 2013).
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Effort-based decision-making is generally studied using tasks that offer a choice between
high effort options leading to highly valued reinforcers vs. low effort/low reward options. In
animal studies, such tasks include a T-maze task that uses a vertical barrier to provide the effortrelated challenge (Salamone et al. 1994; Mott et al. 2009; Pardo et al. 2012), operant procedures
that offer animals a choice between responding on ratio schedules for preferred reinforcers vs.
approaching and consuming a less preferred food (Salamone et al. 1991, 2002; Randall et al.
2012), and effort discounting tasks (Floresco et al. 2008; Bardgett et al. 2009). Several studies in
this area have focused on the effort-related effects of brain dopamine (DA) systems, particularly
accumbens DA. Across multiple tasks, low doses of DA antagonists and accumbens DA
depletions or antagonism shift choice behavior by decreasing selection of the high effort/high
reward option and increasing selection of the low effort/low reward choice (Salamone et al.
1994, 1997, 2007; Nowend et al. 2001; Mai et al. 2012). The effects of DAergic manipulations
on effort-based allocation of responding are not explained by changes in appetite, food
consumption or preference, or discrimination of reward magnitude (Salamone et al. 1991, 1994,
2002; Cousins et al. 1996; Sink et al. 2008; Randall et al. 2012). Furthermore, the effort-related
effects of DA antagonism can be reversed by co-administration of adenosine A2A antagonists
such as istradefylline, MSX-3 and MSX-4 (Farrar et al. 2007, 2010; Salamone et al. 2009; Mott
et al. 2009; Worden et al. 2009; Nunes et al. 2010; Santerre et al. 2012).
It has been suggested that tasks measuring effort-based decision making could be used to
model the effort-related motivational symptoms of depression (Salamone et al. 2006, 2007).
People with depression and related disorders not only display alterations in mood or affect, but
also can show profound motivational impairments (e.g. psychomotor retardation, anergia,
fatigue; Stahl 2002). Tests of effort-related decision making have been developed in humans

	
  

32

(Treadway and Zald 2009), and recent studies have shown that people with major depression
show reduced selection of high effort alternatives (Treadway et al. 2012b). The present work
investigated the effort-related effects of tetrabenazine, which is an inhibitor of VMAT-2
(vesicular monoamine transporter- type 2). By inhibiting VMAT-2, tetrabenazine blocks
vesicular storage and depletes monoamines, though its greatest impact is upon striatal DA
(Pettibone et al. 1984; Tanra et al. 1995). Tetrabenazine is used to treat Huntington’s disease,
but major side effects include depressive symptoms such as fatigue (Frank 2009, 2010; Guay
2010). Tetrabenazine has frequently been used in studies involving animal models of depression
(Preskorn et al. 1984; Kent et al. 1986; Wang et al. 2010), and the present studies assessed the
effects of tetrabenazine on performance of a concurrent progressive ratio (PROG)/chow feeding
choice task (Randall et al. 2012). With this task, rats have the choice of lever pressing reinforced
by more preferred high-carbohydrate pellets vs. approaching and consuming a less preferred
laboratory chow. This choice procedure is useful because the PROG schedule requires that the
animal repeatedly makes within-session choices between lever pressing and chow intake under
conditions in which the ratio requirement is gradually increasing. Previous work with this task
demonstrated that the DA D2 family antagonist haloperidol suppressed PROG lever pressing,
highest ratio achieved, and time spent responding, but did not suppress chow intake (Randall et
al. 2012). These effects of DA antagonism differed substantially from administration of the
cannabinoid CB1 inverse agonist and putative appetite suppressant AM251, and also differed
from the effects of reinforcer devaluation by pre-feeding, both of which substantially suppressed
chow intake under conditions that also reduced lever pressing (Randall et al. 2012). As well as
studying the effects of tetrabenazine in the present work, additional drugs were administered so
their effects could be compared with tetrabenazine (the D1 antagonist ecopipam, the D2
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antagonist eticlopride, and the CB1 receptor neutral antagonist AM4113). Finally, several
putative and established antidepressant drugs (MSX-3, bupropion, deprenyl, tolcapone) were
assessed for their ability to reverse the effects of tetrabenazine. This work was conducted in
order to work towards the development of animal models of the effort-related motivational
symptoms of depression and other disorders (Salamone et al. 2006, 2007; Nunes et al. 2013).

Materials and Methods:
Animals:
94 adult male Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) were housed in a
colony at 23 °C with 12-h light/dark cycles (lights on at 0:700 h). Rats weighed 300–350 g at the
beginning of the study, and were initially food deprived to 85% of their free-feeding body weight
for training. Rats were fed supplemental chow to maintain weight throughout the study, with
water available ad libitum in the home cages. Despite food restriction, rats were allowed modest
weight gain throughout the experiment. All animal protocols were approved by the University of
Connecticut Institutional Animal Care and Use Committee, and followed NIH guidelines.

Pharmacological Agents and Dose Selection:
The DA D1 antagonist ecopipam (Tocris Bioscience, Minneapolis, MN) was dissolved in
0.9% saline that also served as the vehicle control ecopipam. The DA D2 antagonist eticlopride
(Tocris Bioscience) was dissolved in 0.9% saline that also served as the vehicle control for
eticlopride. The VMAT-2 inhibitor tetrabenazine (Tocris Bioscience) was dissolved in a solution
of 20% dimethylsulfoxide (DMSO) and saline and then titrated with 1N HCl and sonicated until
dissolved. A pH matched vehicle solution of 20% DMSO and saline was used for the vehicle
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control for TBZ. The adenosine A2A antagonist MSX-3 was synthesized in the laboratory of
Christa Muller (University of Bonn, Bonn, Germany) and was dissolved in 0.9% saline solution
and then pH adjusted with 1N NaOH to a final pH of 7.4. Saline served as the vehicle control for
MSX-3. The DA uptake inhibitor Bupropion hydrochloride (Alfa Aesar, Ward Hill, MA) was
dissolved in 0.9% saline that also served as the vehicle control for bupropion. The MAO-B
inhibitor Deprenyl hydrochloride (Tocris Bioscience) was dissolved in 0.9% saline that also
served as the vehicle control for deprenyl. The COMT inhibitor Tolcapone (Toronto Research
Chemicals, Toronto Canada) was dissolved in 0.9% saline solution and then titrated with Tween
80 and sonicated until dissolved. Saline was used as the vehicle control for Tolcapone. AM4113
was synthesized in the laboratory of Alex Makriyannis (Center for Drug Discovery, Northeastern
University, Boston, MA). AM4113 was dissolved in DMSO, Tween 80, and 0.9% saline at a
ratio of 1:1:8. All doses were selected based on previous work (Sink et al., 2008; Salamone et al.,
2009; Nunes et al., 2010, Randall et al., 2011, 2012) or from unpublished preliminary studies
from this lab. All drugs were administered intraperitoneal (IP).

Behavioral Procedures:
Behavioral sessions were conducted in operant conditioning chambers (28x23x23 cm3;
Med Associates). Rats were initially trained to lever press on a continuous reinforcement
schedule (30-min sessions; 45-mg pellets, Bioserve, Frenchtown, NJ, USA) for 1 week, and then
were shifted to the PROG schedule (30-min sessions, 5 days/week) for several additional weeks.
For PROG sessions, the ratio started at FR1 and was increased by one additional response every
time 15 reinforcements were obtained (FR1x15, FR2x15, FR3x15,…). Additionally, this
schedule included a “time-out” feature that deactivated the response lever if 2 minutes elapsed
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without a ratio being completed. Upon reaching stable baseline responding, chow was then
introduced. Weighed amounts of laboratory chow (Laboratory Diet, 5P00 Prolab RMH 3000,
Purina Mills, St. Louis, MO, USA; typically 15–20 g) were concurrently available on the floor of
the chamber during the PROG sessions. At the end of the session, rats were removed from the
chamber, and food intake was determined by weighing the remaining food (including spillage).
Rats were trained until they attained stable levels of baseline lever pressing and chow intake,
after which drug testing began. For most baseline days rats did not receive supplemental feeding,
however, over weekends and after drug tests, rats received supplemental chow in the home cage.
On baseline and drug treatment days, rats normally consumed all the operant pellets that were
delivered during each session.

Experimental Procedures:
For all experiments, animals received a vehicle injection 1 week prior to beginning
testing in order to habituate them to being injected. All experiments used a within-group design
in which each rat received all drug or vehicle treatments (IP) in their particular experiment in a
randomly varied order (one treatment per week). Baseline training sessions (i.e., non-drug) were
conducted 4 days per week.

Experiments 1-4: Effort-related effects of TBZ: Comparison with other drugs
Experiment 1: Effects of TBZ
On test days, rats (n = 14) received injections of 0.25, 0.5, 0.75, 1.0 mg/kg TBZ or
vehicle, 90 minutes prior to testing.
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Experiment 2: Effects of the DA D1 antagonist ecopipam
On test days, rats (n = 12) received injections of 0.05, 0.1, 0.2 mg/kg ecopipam or
vehicle, 30 minutes prior to testing.

Experiment 3: Effects of the DA D2 antagonist eticlopride
On test days, rats (n = 16) received injections of 0.02, 0.04, 0.08 mg/kg eticlopride or
vehicle, 30 minutes prior to testing.

Experiment 4: Effects of the cannabinoid CB1 antagonist and putative appetite suppressant
AM4113
On test days, rats (n = 16) received injections of 4.0, 8.0, 16.0 mg/kg AM4113 or vehicle,
30 minutes prior to testing.

Experiments 5-8: Effort-related effects of TBZ: Reversal experiments
Experiment 5: Ability of the adenosine A2A antagonist MSX-3 to reverse the effects of TBZ
On test days, rats (n = 8) received an injection of 0.75 mg/kg TBZ or vehicle 90 minutes
prior to testing and an injection of 0.5, 1.0, 2.0 mg/kg MSX-3 or vehicle 30 minutes prior to
testing.

Experiment 6: Ability of the DA uptake inhibitor bupropion to reverse the effects of TBZ
On test days, rats (n = 10) received an injection of 0.75 mg/kg TBZ or vehicle 90 minutes
prior to testing and an injection of 5.0, 10.0, 15.0 mg/kg bupropion or vehicle 30 minutes prior to
testing.

	
  

37

Experiment 7: Ability of the MAO-B inhibitor deprenyl to reverse the effects of TBZ
On test days, rats (n = 10) received an injection of 0.75 mg/kg TBZ or vehicle 90 minutes
prior to testing and an injection of 2.5, 5.0, 10.0 mg/kg deprenyl or vehicle 30 minutes prior to
testing.

Experiment 8: Ability of the COMT inhibitor tolcapone to reverse the effects of TBZ
On test days, rats (n = 8) received an injection of 0.75 mg/kg TBZ or vehicle 90 minutes
prior to testing and an injection of 10.0, 20.0, 30.0 mg/kg tolcapone or vehicle 60 minutes prior
to testing.

Statistical Analyses:
For each experiment, total number of lever presses, highest ratio achieved, active lever
time (in seconds) and gram quantity of chow consumption were analyzed with repeated measures
ANOVA. To determine differences between treatment conditions, non-orthogonal planned
comparisons using the error term from the overall ANOVA (Keppel, 1991) was used. In order to
assess differences between performance groups (high and low performers), each experimental
group was divided in half using a median split of vehicle lever pressing for that experiment.
Using this split, total number of lever presses, highest ratio achieved, active lever time and gram
quantity of chow consumed were analyzed with repeated measures factorial ANOVA using
performance group as the between subjects variable. Interactions for these analyses are
presented; a significant interaction means that the drug treatment effect differed across the
performance groups.
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Results:
Experiment 1: The VMAT-2 inhibitor TBZ decreases PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA revealed a significant effect of
treatment on total lever presses (F[4,52] = 4.204, p < 0.05, Figure 3.1A). Non-orthogonal
planned comparisons revealed that total lever presses were significantly decreased at 0.50, 0.75
and 1.0 mg/kg TBZ compared to vehicle (p < 0.05). Repeated measures ANOVA also revealed
that there was a significant effect of TBZ on highest ratio achieved (F[4,52] = 8.135, p < 0.05,
Figure 3.1B). Planned comparisons showed that highest ratio achieved was significantly
decreased at 0.50, 0.75 and 1.0 mg/kg TBZ compared to vehicle (p < 0.05). There also was a
significant overall effect of treatment on active lever time (F[4,52] = 6.549, p < 0.05, Figure
3.1C), with 0.50, 0.75 and 1.0 mg/kg TBZ significantly differing from vehicle (p < 0.05).
Repeated measures ANOVA revealed no significant effect of TBZ on chow consumption
(F[4,52] = 2.603, n.s., Figure 3.1D).
Analyses Separating High and Low Performers. Additional analyses were performed
separating high and low performers into two separate groups, and using performance group as a
factor in a factorial ANOVA. With these analyses, a significant performance group x treatment
interaction indicates that the drug treatment effect was different for high vs. low performers.
There was a significant performance group interaction for total lever presses (F[4,48] = 4.242, p
< 0.05), highest ratio achieved (F[4,48] = 7.378, p < 0.05), active lever time (F[4,48] = 6.458, p
< 0.05) and chow consumption (F[4,48] = 4.296, p < 0.05).
As a result of these significant interactions, separate repeated measures ANOVA were
conducted on each performance group. In high performers, these additional analyses revealed a
significant effect of TBZ on total lever presses (F[4,24] = 4.247, p < 0.05), highest ratio achieved
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(F[4,24] = 10.425, p < 0.05), active lever time (F[4,24] = 9.828, p < 0.05) and chow
consumption(F[4,24] = 5.000, p < 0.05). Non-orthogonal planned comparisons revealed that
TBZ reduced total lever presses in high performers at 0.5, 0.75 and 1.0 mg/kg compared to
vehicle (p < 0.05). Furthermore, TBZ reduced highest ratio achieved and active lever time in
high performers at all doses tested compared to vehicle (p < 0.05). Moreover, TBZ increased
chow consumption in high performers at 0.5, 0.75 and 1.0 mg/kg doses compared to vehicle (p <
0.05). In contrast, repeated measures ANOVA revealed that TBZ only affected total lever presses
in low performers (F[4,24] = 4.769, p < 0.05). Non-orthogonal planned comparisons showed that
total lever presses were decreased at 0.75 and 1.0 mg/kg TBZ compared to vehicle (p < 0.05).
In addition, each measure was analyzed using univariate ANOVA with group as the fixed
factor. These analyses revealed that the source of the interaction in total lever presses was that
high responders responded significantly more on vehicle compared to low responders (F[1,12] =
5.129, p < 0.05). Furthermore, the interaction in highest ratio achieved was the result of high
responders reaching higher ratios on vehicle (F[1,12] = 12.826, p < 0.05) and 0.25 mg/kg TBZ
(F[1,12] = 5.095, p < 0.05). Moreover, the interaction in active lever time was due to high
responders keeping the lever active for longer on vehicle (F[1,12] = 12.442, p < 0.05) compared
to low responders. Finally, the interaction in chow consumption was due to high responders
consuming significantly less chow on vehicle (F[1,12] = 10.661, p < 0.05) and 0.25 mg/kg
(F[1,12] = 5.105, p < 0.05) TBZ compared to low responders.

Experiment 2: The DA D1 antagonist Ecopipam decreases PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA revealed a significant effect of
treatment on total lever presses (F[3,33] = 6.610, p < 0.05, Figure 3.3A). Planned comparisons
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showed that ecopipam significantly decreased total lever presses at 0.05, 0.1 and 0.2 mg/kg
compared to vehicle (p < 0.05). There was a significant effect of treatment on highest ratio
achieved (F[3,33] = 16.134, p < 0.05, Figure 3.3B), with planned comparisons demonstrating
that highest ratio achieved was significantly decreased at 0.05, 0.1 and 0.2 mg/kg ecopipam
compared to vehicle (p < 0.05). There also was a significant effect of treatment on active lever
time (F[3,33] = 5.667, p < 0.05, Figure 3.3C). Active lever time was significantly decreased at
0.1 and 0.2 mg/kg ecopipam compared to vehicle (p < 0.05, planned comparisons). In addition,
there was a significant effect of treatment on chow consumption (F[3,33] = 5.426, p < 0.05,
Figure 3.3D). Non-orthogonal planned comparisons revealed that chow consumption was
significantly increased at 0.1 and 0.2 mg/kg ecopipam compared to vehicle (p < 0.05).
Analyses Separating High and Low Performers. Repeated measures factorial ANOVA
(i.e., separating animals by performance group) revealed a significant interaction effect total
lever presses (F[3,30] = 6.250, p < 0.05), and highest ratio achieved (F[3,30] = 7.873, p < 0.05),
but not for active lever time (F[3,30] = 1.442, n.s.) or chow intake (F[3,30] = 2.478, n.s.).

Experiment 3: The DA D2 antagonist Eticlopride decreases PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA revealed a significant effect of
treatment on total lever presses (F[3,45] = 4.667, p < 0.05, Figure 3.4A). Non-orthogonal
planned comparisons revealed that eticlopride significantly decreased total lever presses at 0.04
and 0.08 mg/kg compared to vehicle (p < 0.05). There also was a significant effect of treatment
on highest ratio achieved (F[3,45] = 9.973, p < 0.05, Figure 3.4B). Non-orthogonal planned
comparisons revealed that eticlopride significantly decreased highest ratio achieved at 0.04 and
0.08 mg/kg compared to vehicle (p < 0.05). There was a significant overall treatment effect on
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active lever time (F[3,45] = 6.947, p < 0.05, Figure 3.4C). Non-orthogonal planned comparisons
revealed that active lever time was aignificantly decreased by eticlopride at 0.08 mg/kg
compared to vehicle (p < 0.05). However, there was no effect effect of treatment on chow
consumption (F[3,45] = 1.947, n.s., Figure 3.4D).
Analyses Separating High and Low Performers. Factorial ANOVA revealed a significant
interaction effect for total lever presses (F[3,42] = 5.819, p < 0.05), highest ratio achieved
(F[3,42] = 7.931, p < 0.05), and active lever time (F[3,42] = 8.640, p < 0.05), but not for chow
intake (F[3,42] = 0.959, n.s.).

Experiment 4: The cannabinoid CB1 antagonist AM4113 decreases both lever pressing and
chow consumption
Analyses of Total Group. Repeated measures ANOVA revealed a significant effect of
AM4113 on total lever presses (F[3,45] = 3.496, p < 0.05, Figure 3.5A). Non-orthogonal planned
comparisons demonstrated that AM4113 decreased total lever presses at 8.0 and 16.0 mg/kg
compared to vehicle (p < 0.05). There also was a significant effect of AM4113 on highest ratio
achieved (F[3,45] = 8.511, p < 0.05, Figure 3.5B), and planned comparisons demonstrated that
AM4113 decreased highest ratio achieved at 8.0 and 16.0 mg/kg compared to vehicle (p < 0.05).
Active lever time was not affected by AM4113 (F[3,45] = 0.139, n.s., Figure 3.5C), however,
there was a significant effect of AM4113 on chow consumption (F[3,45] = 16.559, p < 0.05,
Figure 3.5D). Planned comparisons revealed that AM4113 decreased chow consumption at 8.0
and 16.0 mg/kg compared to vehicle (p < 0.05).
Analyses Separating High and Low Performers. Factorial ANOVA revealed a significant
performance group x treatment interaction effect for total lever presses (F[3,42] = 3.487, p <
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0.05), and highest ratio achieved (F[3,42] = 5.800, p < 0.05), but no significant interaction for
chow consumption (F[3,42] = 0.458, n.s.) or active lever time (F[3,42] = 0.200, n.s.).

Experiment 5: MSX-3 reverses the effects of TBZ on PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA revealed a significant effect of
treatment on total lever presses (F[4,28] = 4.586, p < 0.05, Figure 3.6A). Non-orthogonal
planned comparisons revealed that TBZ significantly decreased total lever presses compared to
vehicle (p < 0.05), and that 1.0 and 2.0 mg/kg MSX-3 plus TBZ significantly increased total
lever presses compared to TBZ alone (p < 0.05). There also was a significant effect of treatment
on highest ratio achieved (F[4,28] = 6.867, p < 0.05, Figure 3.6B). Planned comparisons
revealed that TBZ significantly decreased highest ratio achieved compared to vehicle (p < 0.05),
and 1.0 and 2.0 mg/kg MSX-3 plus TBZ significantly increased highest ratio achieved compared
to TBZ alone (p < 0.05). ANOVA showed there was a significant effect of treatment on active
lever time (F[4,28] = 3.862, p < 0.05, Figure 3.6C). TBZ significantly decreased active lever
time compared to vehicle (p < 0.05), and 1.0 and 2.0 mg/kg MSX-3 plus TBZ significantly
differed from TBZ alone (p < 0.05). There was no significant treatment effect for chow
consumption (F[4,28] = 0.102, n.s., Figure 3.6D).
Analyses Separating High and Low Performers. Factorial ANOVA revealed a significant
performance group x treatment interaction effect for total lever presses (F[4,24] = 2.769, p =
0.05), but not for highest ratio achieved (F[4,24] = 1.765, n.s.), active lever time (F[4,24] =
0.655, n.s.), chow consumption (F[4,24] = 0.787, n.s.).

Experiment 6: Bupropion reverses the effects of TBZ on PROG/chow performance
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Analyses of Total Group. Repeated measures ANOVA demonstrated a significant effect
of treatment on total lever presses (F[4,40] = 7.683, p < 0.05, Figure 3.7A). Planned comparisons
revealed that total lever presses was significantly decreased by TBZ compared to vehicle (p <
0.05), and that total lever presses were significantly increased at 15.0 mg/kg bupropion plus TBZ
compared to TBZ alone (p < 0.05). There also was a significant effect of treatment on highest
ratio achieved (F[4,40] = 14.364, p < 0.05, Figure 3.7B). Planned comparisons showed that
highest ratio achieved was significantly decreased by TBZ compared to vehicle (p < 0.05), and
that 15.0 mg/kg bupropion plus vehicle significantly differed from TBZ alone (p < 0.05). Active
lever time also showed a significant overall effect of treatment (F[4,40] = 5.416, p < 0.05, Figure
3.7C); this measure was significantly decreased by TBZ compared to vehicle (p < 0.05), and 15.0
mg/kg bupropion plus TBZ differed from TBZ alone (p < 0.05). There was a significant effect
of treatment on chow consumption (F[4,40] = 9.041, p < 0.05, Figure 3.7D), but the only
significant planned comparison was that chow intake was significantly decreased by 15.0 mg/kg
bupropion compared to TBZ alone (p < 0.05).
Analyses Separating High and Low Performers. There was a significant treatment by
performance group interaction for total lever presses (F[4,32] = 5.730, p < 0.05), and highest
ratio achieved (F[4,32] = 4.524, p < 0.05), but no significant interaction for active lever time
(F[4,32] = 0.877, n.s.). Furthermore, there was a significant treatment by group interaction in
chow consumption (F[4,32] = 5.334, p < 0.05).

Experiment 7: Deprenyl reverses the effects of TBZ on PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA showed there was a significant
effect of treatment on total lever presses (F[4,36] = 6.172, p < 0.05, Figure 3.8A). Planned
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comparisons demonstrated that total lever presses were decreased by TBZ compared to vehicle
(p < 0.05), and 5.0 mg/kg deprenyl plus TBZ significantly differed from TBZ alone (p < 0.05).
There also was a significant effect of treatment highest ratio achieved (F[4,36] = 5.176, p < 0.05,
Figure 3.8B), with planned comparisons demonstrating that highest ratio achieved was
significantly decreased by TBZ compared to vehicle (p < 0.05), while 5.0 mg/kg deprenyl plus
TBZ significantly differed from TBZ alone (p < 0.05). Active lever time also was significantly
affected by drug treatment (F[4,36] = 3.073, p < 0.05, Figure 3.8C). TBZ significantly
suppressed active lever time compared to vehicle (p < 0.05), and all doses of deprenyl plus TBZ
were capable of increasing active lever time compared to TBZ alone. In addition, there was a
significant effect of treatment on chow consumption (F[4,36] = 3.039, p < 0.05, Figure 3.8D),
with chow consumption being significantly lower in the 10.0 mg/kg deprenyl plus TBZ condition
compared to TBZ alone (p < 0.05).
Analyses Separating High and Low Performers. Factorial ANOVA revealed a significant
treatment x performance group interaction for total lever presses (F[4,32] = 9.028, p < 0.05),
highest ratio achieved (F[4,32] = 5.979, p < 0.05), but not for active lever time (F[4,32] = 1.557,
n.s.). Furthermore, there was a significant treatment by group interaction in chow consumption
(F[4,32] = 2.911, p < 0.05).

Experiment 8: Tolcapone fails to reverse the effects of TBZ on PROG/chow performance
Analyses of Total Group. Repeated measures ANOVA revealed a significant effect of
treatment on total lever presses (F[4,28] = 3.435, p < 0.05, Figure 3.9A) and highest ratio
achieved (F[4,28] = 7.229, p < 0.05, Figure 3.9B), but no significant effect of treatment on active
lever time (F[4,28] = 2.565, n.s., Figure 3.9C), or chow consumption (F[4,28] = 0.458, n.s.,
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Figure 3.9D). TBZ significantly differed from vehicle for total lever presses and highest ratio
achieved, but tolcapone failed to significantly reverse any of the effects of TBZ.
Analyses Separating High and Low Performers. Repeated measures factorial ANOVA
revealed there was a significant treatment by performance group interaction for total lever
presses (F[4,24] = 3.023, p < 0.05), highest ratio achieved (F[4,24] = 3.932, p < 0.05), and active
lever time (F[4,24] = 2.904, p < 0.05), but not chow consumption (F[4,24] = 0.503, n.s.).
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Figure 3.1: Effects of the VMAT-2 inhibitor and DA depleting agent TBZ on PROG/chow
performance. On measures of lever pressing, mean (+SEM) total lever presses (A), highest ratio
achieved (B), and active lever time (measured in seconds, C), TBZ produced significant
decreases at 0.5, 0.75 and 1.0 mg/kg. Chow consumption (mean +SEM, in grams) during test
sessions was unaffected by any dose tested (D). (* p < 0.05, different from vehicle).
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Figure 3.2: High Responder/Low Responder Breakdown of TBZ effects. Mean (+ SEM) total
lever presses (A), highest ratio achieved (B), active lever time (C) and chow consumption (D)
between high and low responders. TBZ showed a greater effect on high responders than low
responders. (* p < 0.05, difference between groups)
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Figure 3.3: Effects of the DA D1 antagonist ecopipam on PROG/chow performance. On
measures of lever pressing, mean (+SEM) total lever presses (A), highest ratio achieved (B), and
active lever time (measured in seconds, C), ecopipam produced significant decreases at 0.1 and
0.2 mg/kg. Chow consumption (mean +SEM, in grams) during test sessions was unaffected by
any dose tested (D). (* p < 0.05, different from vehicle).
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Figure 3.4: Effects of the DA D2 antagonist eticlopride on PROG/chow performance. Mean
(+SEM) total lever presses (A) and highest ratio achieved (B) were significantly decreased by
0.04 and 0.08 mg/kg of eticlopride. Additionally, active lever time (measured in seconds, C) was
significantly reduced at 0.08 mg/kg eticlopride. Chow consumption (mean +SEM, in grams)
during test sessions was unaffected by any dose tested (D). (* p < 0.05, different from vehicle).

	
  

49

A

800
600
400

*

200
0
VEH

4

8

Maximum Ratio Achieved

Lever Presses (30 min)

1000

12
10

B

8
6

*

4
2
0
VEH

16

1000

Chow Consumption (g)

Active Lever Time (s)

1200

C

800
600
400
200
0
VEH

4

8

16

Dose AM4113 (mg/kg IP)

4

8

16

Dose AM4113 (mg/kg IP)

Dose AM4113 (mg/kg IP)
12
10

D

8

*

6

*

4

*

2
0
VEH

4

8

16

Dose AM4113 (mg/kg IP)

Figure 3.5: Effects of the cannabinoid CB1 antagonist and putative appetite suppressant AM4113
on PROG/chow performance. Mean (+SEM) total lever presses (A) and highest ratio achieved
(B) were significantly decreased by 16.0 mg/kg of AM4113. Active lever time (measured in
seconds, C) was not affected by AM4113 at any dose tested. Chow consumption (mean +SEM,
in grams) was significantly reduced at 4.0, 8.0 and 16.0 mg/kg of AM4113 (D). (* p < 0.05,
different from vehicle).
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Figure 3.6: The adenosine A2A antagonist MSX-3 reverses the effects of TBZ on the
PROG/Chow procedure. On measures of lever pressing, mean (+SEM) total lever presses (A),
highest ratio achieved (B), and active lever time (measured in seconds, C), TBZ produced
significant decreases at 0.75 mg/kg. Chow consumption (mean +SEM, in grams) during test
sessions was unaffected by TBZ (D). MSX-3 reversed the effects on total lever presses, highest
ratio achieved and active lever time at both 1.0 and 2.0 mg/kg. (# p < 0.05, different from
vehicle; * p < 0.05, different from TBZ alone).
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Figure 3.7: The DA uptake inhibitor and common antidepressant bupropion reverses the effects
of TBZ on the PROG/Chow procedure. On measures of lever pressing, mean (+SEM) total lever
presses (A), highest ratio achieved (B), and active lever time (measured in seconds, C), TBZ
produced significant decreases at 0.75 mg/kg. Chow consumption (mean +SEM, in grams)
during test sessions was unaffected by TBZ (D). Bupropion reversed the effects on total lever
presses, highest ratio achieved and active lever time at 15.0 mg/kg. (# p < 0.05, different from
vehicle; * p < 0.05, different from TBZ alone).
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Figure 3.8: The MAO-B inhibitor and putative antidepressant deprenyl reverses the effects of
TBZ on the PROG/Chow procedure. On measures of lever pressing, mean (+SEM) total lever
presses (A), highest ratio achieved (B), and active lever time (measured in seconds, C), TBZ
produced significant decreases at 0.75 mg/kg. Chow consumption (mean +SEM, in grams)
during test sessions was unaffected by TBZ (D). Deprenyl reversed the effects on total lever
presses, highest ratio achieved at 5.0 mg/kg. In addition, active lever time was increased at 2.5,
5.0 and 10.0 mg/kg. Chow consumption was significantly decreased at 10 mg/kg. (# p < 0.05,
different from vehicle; * p < 0.05, different from TBZ alone).
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Figure 3.9: The COMT inhibitor Tolcapone fails to reverse the effects of TBZ on the
PROG/Chow procedure. On measures of lever pressing, mean (+SEM) total lever presses (A),
highest ratio achieved (B), and active lever time (measured in seconds, C), TBZ produced
significant decreases at 0.75 mg/kg. Chow consumption (mean +SEM, in grams) during test
sessions was unaffected by TBZ (D). Tolcapone did not reverse the effects on total lever presses,
highest ratio achieved or active lever time at any dose tested (# p < 0.05, different from vehicle).
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Chapter 4 – Experiments with the Flinders Sensitive Line
The Flinders Sensitive Line (FSL) was first developed for the study of anticholinesterase
pesticides (Overstreet et al., 1979). It was noted however that these rats also displayed many
traits similar to depressed patients, including disrupted sleep cycles, enhanced REM sleep and a
sensitivity to cholinergic stimulation (Janowski et al., 1980). As a result, researchers began using
FSL rats to study depression. Early work utilized traditional behavioral models of depression
including the forced swim and tail suspension tests. FSL rats showed exaggerated responses on
both of these tasks including reduced swim and struggle time compared to normal SpragueDawley controls (Overstreet et al., 1993). Furthermore, treatment with common antidepressant
drugs improves these responses, bringing FSL rats up to control levels (Overstreet et al., 2003).
Based upon these results, many studies suggested that FSL rats would be a useful animal model
of depression.
All of the studies to date have focused on the mood related symptoms of depression. With
growing interest in understanding the effort related symptoms of depression (Salamone et al.,
2003, 2006; Treadway and Zald, 2011), it is important to assess whether or not the FSL rats
demonstrate any form of effort-related motivational impairment. The studies that follow sought
to answer this question by testing FSL and Sprague-Dawley control animals through a series of
behavioral tasks. Both FSL and control rats were first trained on a continuous reinforcement
(CRF) task to assess basic operant responding. Because of the low effort requirements of the
CRF schedule, it was hypothesized that there would be no difference in CRF responding between
FSL and controls. The next set of experiments examined differences in progressive ratio (PROG)
responding. It was hypothesized that FSL rats would show reduced responding on the PROG, but
show preserved chow intake. Moreover, parallel studies (feeding probe tests) examined whether
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or not FSL animals showed normal levels of consumption of high carbohydrate pellets, and
normal preference of pellets over chow, compared to controls. Following PROG/Chow training
all animals were trained on a fixed ratio 20 (FR20), which produces a high rate of responding in
normal SD rats. It was hypothesized that once again, FSL rats would show reduced response rate
compared to controls. It was hypothesized that FSL rats would not show any difference in freefood intake compared to controls, but would show effort-related impairments (i.e., selective
suppression of PROG lever pressing). Finally, in order to assess any differences in baseline
anxiety, both groups were tested on the open field and the elevated plus maze. Because of the
clinical overlap between anxiety and depression, and because some animal models of depression
are accompanied by anxiogenic effects (e.g. Wistar Kyoto rats), it was hypothesized that FSL
rats would show a greater anxiety response compared to controls on both measures.

Materials and Methods:
Animals:
16 FSL rats were purchased from Duke University (Durham, NC). In addition, 20 age
and weight matched Sprague-Dawley rats were purchased from Harlan (North America Branch).
Rats were pair housed in a colony maintained at 23oC on a 12-hour light dark cycle (lights on at
09:00). Rats weighed 350-400 g at the beginning of the study, and were initially food deprived to
85% of their free-feeding body weight for training. Rats were fed supplemental chow to maintain
weight throughout each study, with water available ad libitum in the home cages. Despite food
restriction, rats were allowed modest weight gain throughout these experiments. All animal
protocols were approved by the University of Connecticut Institutional Animal Care and Use
Committee, and followed NIH guidelines.
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Behavioral Procedures:
CRF Training:
Behavioral sessions were conducted in operant conditioning chambers (28x23x23 cm3;
Med Associates). Rats were initially trained to lever press on a continuous reinforcement
schedule (30-min sessions; 45-mg pellets, Bioserve, Frenchtown, NJ, USA) for 3 weeks.
Progressive Ratio, PROG/Chow Training:
Following week 3 of CRF training, all rats were shifted to the PROG schedule (30-min
sessions, 5 days/week) for 9 weeks. For PROG sessions, the ratio started at FR1 and was
increased by one additional response every time 15 reinforcements were obtained (FR1x15,
FR2x15, FR3x15,…). Additionally, this schedule included a “time-out” feature that deactivated
the response lever if 2 minutes elapsed without a ratio being completed.
Following the 9th week, chow was introduced into the chambers. Weighed amounts of
laboratory chow (Laboratory Diet, 5P00 Prolab RMH 3000, Purina Mills, St. Louis, MO, USA;
typically 15–20 g) were concurrently available on the floor of the chamber during the PROG
sessions. At the end of the session, rats were removed from the chamber, and food intake was
determined by weighing the remaining food (including spillage). Rats were trained until they
attained stable levels of baseline lever pressing and chow intake, after which drug testing began.
For most baseline days rats did not receive supplemental feeding, however, over weekends and
after drug tests, rats received supplemental chow in the home cage. On baseline and drug
treatment days, rats normally consumed all the operant pellets that were delivered during each
session.
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FR20 Training:
Following week 5 of PROG/chow training, all rats were shifted to a fixed ratio 20 (FR20)
schedule for an additional 3 weeks.
Free Feeding Probe Trials:
Feeding trials took place in plexiglass chambers (23x28x28 cm3). Weighed amounts of
pellets, chow, or both were placed in the chambers and rats were allowed 30 minutes to eat.
Probe trials took place on non-operant training days (i.e., weekends). At the end of each trial, all
remaining food (including spillage) was collected and weighed to determine total consumption.
Open Field Arena:
For open field testing, rats were placed, individually, into the arena and allowed 10
minutes to freely explore. Sessions were filmed by a video camera mounted above the arena. The
room was dark with the exception of two low intensity red lamps used to produce enough light
for the camera to capture the session. The floor of the arena was divided into 25 squares (5x5).
Any activity in the 9 central squares was considered inner activity while anything occurring in
the 16 perimeter squares was considered outer activity. A crossing was only counted when all 4
paws moved into an adjacent square. In addition to inner/outer crossings, rats were also analyzed
for rearing counts, urine (yes/no) and number of fecal bola for each session.

Elevated Plus Maze:
Animals were placed, individually, into the center of the maze facing into a closed arm,
and then were allowed 5 minutes to freely explore. Sessions were recorded by a video camera
mounted above the maze. The room was dark with the exception of two low intensity red lamps
used to produce enough light for the camera to capture the session. Entrances into open or closed
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arms were only counted when all 4 paws crossed into an area. In addition to open/closed
entrances, rats were also analyzed for time spent in open versus closed arms, urine (yes/no) and
number of fecal bola for each session.

Experimental Procedures:
Experiment 1: Comparison of FSL rats to SD controls on basic operant responding
All rats were trained for 3 weeks on the CRF procedure described above. For each day,
total lever presses were recorded for each animal. In addition, operant sessions were divided into
5-minute time periods to analyze patterns of responding across the session between groups.

Experiment 2: Comparison of FSL to SD controls on Progressive Ratio and PROG/chow
responding
All rats were trained on the progressive ratio procedure (PROG15) described in chapter 2.
For each session, total lever presses, maximum ratio achieved and active lever time were
recorded. Following week 9, all rats moved to the PROG/chow procedure described in chapter 2.
In addition to the other variables, chow consumption in grams was recorded for all sessions.

Experiment 3: Comparison of FSL to SD controls on FR20 responding and effects of prefeeding
to reduce food motivation
Following PROG/chow training, all rats were moved to a fixed ratio 20 (FR20) for 3
additional weeks. On days 10 and 15 of FR20 training (the last day of week 2 and week 3), all
rats were pre-fed prior to the session. On day 10, all rats were given access to 4.5 grams of bioserve pellets for 30 minutes, beginning 1 hour prior to the operant session. On day 15, all rats
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were given access to 9 grams of bio-serve pellets for 30 minutes, beginning 1 hour prior to the
operant session. For both prefeeding sessions, all rats consumed all pellets within the 30-minute
feeding period. For all sessions, total lever presses and inter-response time (IRT) was recorded.

Experiment 4: Comparison of FSL and SD rats on anxiety indices with elevated plus maze and
open field
Plus maze and open field testing were done on two separate days at different points in
training. For open field sessions, each rat was placed into the center of the arena facing a corner
and then allowed 10 minutes to freely explore. Sessions were recorded by camera so that
observers would not bias the animals’ behavior. For plus maze sessions, rats were placed in the
center of the maze facing into a closed arm and then allowed 5 minutes to freely explore. Again,
sessions were recorded by video camera so that observed would not influence behavior.

Results
Experiment 1: FSL rats respond less on CRF than SD controls
Repeated measures factorial ANOVA revealed that there was a significant effect of week
on total lever presses (F[2,68] = 71.525, p < 0.05). In addition, there was a significant effect of
group on total lever presses (F[1,34] = 44.718, p < 0.05). However, there was no week by group
interaction in total lever presses (F[2,68] = 0.587, n.s.). Post hoc analysis revealed that controls
responded significantly more than FSL rats on all 3 weeks of CRF training (p < 0.05, Figure 4.1)
In addition to analysis of total lever presses, responding on week 3 was broken down into
5-minute periods across each session to analyze satiation between groups. Repeated measures
factorial ANOVA revealed an effect of time period on lever presses (F[5,170] = 248.809, p <
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0.05, Figure 4.2). Furthermore, there was a significant effect of group (F[1,34] = 31.212, p <
0.05). Moreover, there was a significant time-period by group interaction in lever presses
(F[5,170] = 10.154, p < 0.05). Non-orthogonal planned comparisons revealed that in periods 3, 4,
5 and 6 (minutes 10-30 of the session), FSL rats responded significantly less than controls (p <
0.05).

Experiment 2: FSL rats respond less on the progressive ratio but not on the PROG/chow
procedure compared to SD controls

Progressive Ratio Responding (weeks 1-9)
Repeated measures factorial ANOVA revealed a significant effect of week on total
PROG lever presses (F[8,272] = 46.369, p < 0.05, Figure 4.3A). Moreover, there was a
significant effect of group on total lever presses (F[1,34] = 8.300, p < 0.05). Furthermore there
was a significant week by group interaction in total lever presses (F[8,272] = 6.419, p < 0.05).
There was a significant effect of week on highest ratio achieved (F[8,272] = 51.258, p < 0.05,
Figure 4.3B). In addition, there was a significant effect of group on highest ratio achieved
(F[1,34] = 6.363, p < 0.05), and a significant week by group interaction for this variable
(F[8,272] = 6.927, p < 0.05). There also was a significant effect of week on active lever time
(F[8,272] = 2.018, p < 0.05, Figure 4.3C). In addition, there was a significant effect of group on
active lever time (F[1,34] = 5.776, p < 0.05), and a significant week by group interaction
(F[8,272] = 3.090, p < 0.05).
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PROG/Chow Performance (weeks 10-14)
Repeated measures factorial ANOVA showed that there was a significant effect of week
on total lever presses (F[4,136] = 6.144, p < 0.05, Figure 4.4A). However, there was no
significant effect of group on total lever presses (F[1,34] = 1.827, n.s.), and no significant week
by group interaction with this variable (F[4,136] = 1.697, n.s.). Repeated measures factorial
ANOVA revealed a significant effect of week on highest ratio achieved (F[4,136] = 7.681, p <
0.05, Figure 4.4B). Similar to total lever presses, there was no effect of group on highest ratio
achieved (F[1,34] = 1.699, n.s.). Moreover, there was no week by group interaction in highest
ratio achieved (F[4,136] = 0.663, n.s.).
Repeated measures factorial ANOVA revealed no effect of week on active lever time
(F[4,136] = 1.637, n.s., Figure 4.4C). Furthermore, there was no effect of group on active lever
time (F[1,34] = 1.171, n.s.). In addition, there was no week by group interaction in active lever
time (F[4,136] = 1.765, n.s.). Factorial ANOVA also showed a significant effect of week on
chow consumption (F[4,136] = 98.210, p < 0.05, Figure 4.4D). Moreover, there was a
significant effect of group on chow consumption (F[1,34] = 17.448, p < 0.05). FSL rats
consumed significantly less chow than control animals. However, there was no week by group
interaction in chow consumption (F[4,136] = 1.618, n.s.).

Experiment 3: FSL rats respond less on a high rate schedule compared to controls but are not
affected by prefeeding to reduce food motivation
Repeated measures factorial ANOVA revealed a significant effect of week on total lever
presses (F[2,68] = 14.672, p < 0.05, Figure 4.5). Furthermore, there was a significant effect of
group on total lever presses (F[1,34] = 5.328, p < 0.05), with FSL animals responding at lower
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rates. In addition, there was a significant week by group interaction in total lever presses on
FR20 (F[2,68] = 5.265, p < 0.05). Analysis of simple effects demonstrated that there was no
difference between FSL rats and controls in percent baseline responding following 4.5 grams
(F[1,34] = 0.796, n.s.) or 9.0 grams of prefeeding (F[1,34] = 0.302, n.s.).

Experiment 4: FSL rats show reduced appetite compared to controls

Repeated measures factorial ANOVA comparing pellet consumption on pellet probe 1
and 2 revealed a significant effect of probe trial (F[1,34] = 10.140, p < 0.05). Furthermore there
was a significant probe trial by group interaction in pellet consumption (F[1,34] = 7.685, p <
0.05), and a significant effect of group on pellet consumption (F[1,34] = 10.942, p < 0.05). Based
on these results, the pellet probe trials were analyzed separately using univariate ANOVA. This
analysis revealed no difference in pellet consumption between groups on probe trial 1 (F[1,34] =
2.740, n.s., Figure 4.6A). However, on probe trial 2, FSL rats consumed significantly less of the
high carbohydrate pellets compared to controls (F[1,34] = 20.293, p < 0.05, Figure 4.6B).
Moreover, FSL rats consumed significantly less chow on the chow alone probe trial compared to
control rats (F[1,34] = 31.000, p < 0.05, Figure 4.6C).
On the pellet preference probe, univariate ANOVA revealed a significant difference
between groups in grams of pellets consumed (F[1,34] = 26.175, p < 0.05, Figure 4.7A) and total
grams of food consumed between groups (F[1,34] = 35.927, p < 0.05, Figure 4.7A). However,
there was no difference between groups in chow consumption (F[1,34] = 0.279, n.s.). In addition,
FSL rats significantly differed from control rats in terms of relative preference for pellets over
chow (F[1,34] = 4.470, p < 0.05, Figure 4.7B).
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Experiment 5: FSL rats show anxiolytic, not anxiogenic, response compared to controls
Repeated measures factorial ANOVA revealed a significant effect of area (inner vs.
outer) on total crossings (F[1,34] = 239.305, p < 0.05). Furthermore, there was a significant area
by group interaction in crossings (F[1,34] = 28.909, p < 0.05) and a significant effect of group on
total crossings (F[1,34] = 3.081, p < 0.05). Based on these results, inner crossings and outer
crossings were analyzed separately between groups with univariate ANOVA. There was a
significant difference in inner crossings between groups (F[1,34] = 74.714, p < 0.05) with FSL
rats showing more. Furthermore, there was a significant difference between groups in outer
crossings (F[1,34] = 4.177, p < 0.05) with control rats showing more. Furthermore, analysis of
relative inner crossings relative to total crossings, a common measure of anxiety, revealed a
significant difference between groups (F[1,34] = 74.975, p < 0.05; Figure 4.7) with FSL rats
showing more inner crossings relative to total crossings compared to control animals, indicating
they had lower anxiety than the control rats.
Repeated measures factorial ANOVA revealed no significant effect of arm type (open
arm versus closed arm) on total arm entries on the elevated plus maze (F[1,34] = 0.078, n.s.) nor
was there an effect of group on total entries (F[1,34] = 1.296, n.s.). However, there was a
significant arm type by group interaction in total entries (F[1,34] = 40.136, p < 0.05). As such,
univariate ANOVA was used to assess open arm entries and closed arm entries separately
between groups. ANOVA revealed a significant difference between groups in relative open arm
entries (F[1,34] = 11.670, p < 0.05; Figure 4.8), a common measure of anxiety, with FSL rats
showing more, indicating that the FSL animals had lower levels of anxiety. Furthermore, there
was a significant difference in closed arm entries (F[1,34] = 42.405, p < 0.05) with control rats
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showing more. In addition, FSL rats spent more time in the open arms compared to controls
(F[1,34] = 40.351, p < 0.05, Figure 4.9). Moreover, FSL rats traveled to the end of open arms
more than control rats (F[1,34] = 23.252, p < 0.05, Figure 4.10) and performed more head dips
(F[1,34] = 25.234, p < 0.05, Figure 4.11). This pattern of results indicates that FSL rats show
reduced anxiety compared to control animals.
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Figure 4.1: FSL rats respond less on CRF compared to controls. Mean (+SEM) total lever
presses between groups for 3 weeks of CRF training. (* p < 0.05, different from FSL)
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Figure 4.2: FSL rats show more rapid satiation than controls. Mean (+SEM) lever presses
divided into 5-minute periods across the 30-minute session for the last week of CRF responding.
(* p < 0.05, control different from FSL)
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Figure 4.3: FSL rats respond less on the progressive ratio compared to controls. Mean(+SEM)
total lever presses (A), highest ratio achieved (B) and active lever time (C) for 9 weeks of PROG
responding. (* p < 0.05 control difference between groups).
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Figure 4.4: FSL rats compared to controls on PROG/Chow Performance. Mean (+SEM) total
lever presses (A), highest ratio achieved (B), active lever time (C) and chow consumption (D). (*
p < 0.05, control difference between groups).
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Figure 4.5: FSL rats respond less on the FR20 compared to controls. Mean (+SEM) total lever
presses for 3 weeks of FR20 trained between FSL and control rats. (* p < 0.05, difference
between groups)
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Figure 4.6: FSL rats demonstrate reduced appetite compared to controls. FSL and controls did
not differ on probe 1 (Mean (+SEM) grams of pellets consumed, A), but did differ on probe 2
(Mean (+SEM) grams of pellets consumed, B). FSL rats consumed fewer grams of chow on
probe 4 compared to controls (Mean (+SEM) grams of chow consumption, C). (* p < 0.05
difference between groups)
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Figure 4.7: FSL rats consumed fewer grams of pellets than controls (Mean (+SEM) grams of
pellets and chow between groups, A). FSL rats also showed less preference for pellets over chow
compared to controls (Mean (+SEM) amount of pellets consumed expressed as percent of total
food intake, B) (* p < 0.05 difference between groups).
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Figure 4.7: FSL rats show less anxiety response compared to controls. FSL rats showed more
relative inner crossings in the open field arena compared to controls (Mean (+SEM) percent of
total crossings, A). FSL rats also entered the open arm of the plus maze more than the controls
(Mean (+SEM) percent of total entries, B). (* p < 0.05, different from FSL).
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Figure 4.8: FSL rats spend more time in the open arms compared to controls. Mean (+SEM)
seconds spent in open arms during the 5 minute elevated plus maze session. (* p < 0.05,
difference between groups)
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Chapter 5: The effects of the widely used antidepressant bupropion on effort-related
decision making and measures of DA transmission.

Introduction
Over the past decade, researchers and clinicians alike have been placing increasing
emphasis on the effort-related symptoms of depression (Stahl 2002; Salamone et al., 2003, 2006;
Treadway and Zald, 2011). These symptoms include fatigue, anergia, lassitude and psychomotor
slowing, and can been seen in patients diagnosed with depression, multiple sclerosis, Parkinson’s
disease and related disorders. Moreover, these symptoms can be seen in patients being treated for
Huntington’s disease with tetrabenazine (Frank 2009), and patients undergoing cancer
chemotherapy (Dantzer 2012). Importantly, these symptoms are not readily treated by 5-HT
uptake inhibitors.
Evidence from human clinical studies demonstrated that normal subjects treated with
amphetamine, a drug that promotes DA release and prevents uptake, were more likely to work
for rewards compared to controls (Wardle et al., 2011). Moreover, depressed patients tested on
the same task were less likely to work for better rewards, even when the probability of
reinforcement was very high (Treadway et al., 2012). These data are supported by animal studies
demonstrating that rats treated with the DA depleting agent TBZ are less likely to work for either
preferred food pellets (Nunes et al., submitted) or larger rewards (Yohn et al., IN PREP).
Moreover, administration of the DA uptake blocker bupropion reverses these effort-related
impairments (Nunes et al., submitted; Yohn et al., IN PREP).
The current experiments were conducted to assess the catecholamine uptake inhibitor
bupropion for its effects on effort-related choice behavior. 	
  Bupropion was selected because
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clinical evidence indicates that blockade of DA uptake may be relatively effective at treating
effort-related symptoms such as anergia and fatigue in depressed people (Rampello et al. 1991;
Stahl 2002; Demyttenaere et al. 2005; Pae et al. 2007). Because of previous research
implicating nucleus accumbens DA in effort-related decision making, these studies also assessed
the ability of behaviorally relevant doses of bupropion to affect both pre- and postsynaptic
markers of accumbens DA transmission. It was hypothesized that bupropion would significantly
increase PROG lever pressing, and would produce a greater effect in low performers compared
to high performers. Moreover, it was hypothesized that bupropion would significantly increase
DARPP-32 expression at both Thr34 and Thr75 sites in untrained animals compared to vehicle
injection. Furthermore, it was hypothesized that bupropion would significantly increase
extracellular DA in the nucleus accumbens core compared to vehicle injection.

Materials and Methods:
Animals:
72 adult male Sprague-Dawley rats were used for the following experiments. All rats
were housed in a colony at 23 °C with 12-h light/dark cycles (lights on at 0:700 h). Rats in
experiments 1 (n=42) weighed 300–350g at the beginning of the study, and were initially food
deprived to 85% of their free-feeding body weight for training. Rats in this experiment were fed
supplemental chow to maintain weight throughout the study, with water available ad libitum in
the home cages. Despite food restriction, rats were allowed modest weight gain throughout the
experiment. All other rats (n=30) weighed 300-350g at the beginning of the study and had ad
libitum access to lab chow and water in home cages. All animal protocols were approved by the
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University of Connecticut Institutional Animal Care and Use Committee, and followed NIH
guidelines.

Pharmacological Agents and Dose Selection:
Bupropion hydrochloride (Alfa Aesar, Ward Hill, MA) was dissolved in 0.9% saline
solution that also served as the vehicle control. Doses were selected based on reversal studies
(Nunes et al., 2013) and unpublished preliminary studies from our laboratory.

Behavioral Procedures:
Behavioral sessions were conducted in operant conditioning chambers (28x23x23 cm3;
Med Associates). Rats were initially trained to lever press on a continuous reinforcement
schedule (30-min sessions; 45-mg pellets, Bioserve, Frenchtown, NJ, USA) for 1 week, and then
were shifted to the PROG schedule (30-min sessions, 5 days/week) for several additional weeks.
For PROG sessions, the ratio started at FR1 and was increased by one additional response every
time 15 reinforcements were obtained (FR1x15, FR2x15, FR3x15,…). Additionally, this
schedule included a “time-out” feature that deactivated the response lever if 2 minutes elapsed
without a ratio being completed. Upon reaching stable baseline responding, chow was then
introduced. Weighed amounts of laboratory chow (Laboratory Diet, 5P00 Prolab RMH 3000,
Purina Mills, St. Louis, MO, USA; typically 15–20 g) were concurrently available on the floor of
the chamber during the PROG sessions. At the end of the session, rats were removed from the
chamber, and food intake was determined by weighing the remaining food (including spillage).
Rats were trained until they attained stable levels of baseline lever pressing and chow intake,
after which drug testing began. For most baseline days rats did not receive supplemental feeding,
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however, over weekends and after drug tests, rats received supplemental chow in the home cage.
On baseline and drug treatment days, rats normally consumed all the operant pellets that were
delivered during each session.

DARPP-32 Immunocytochemistry
Two hours following drug injection, rats were perfused with 3.7% formaldehyde solution
and brains were extracted. Tissue was fixed in 3.7% formaldehyde overnight and then moved to
a 30% sucrose cryo-protectant solution. 50µm sections were taken using a cryostat freezing
microtome. Tissue was washed in PBS and then bathed in blocking solution (0.1% Triton-X,
5.0% normal donkey serum, PBS) on a rotating shaker for 60 minutes. Tissue was washed for 15
minutes in PBS and then incubated in primary antibody (donkey anti-rabbit Thr34, donkey antirabbit Thr75, 1:500; donkey anti-mouse ENK, donkey anti-goat SP, 1:200, Santa Cruz
Bioscience, CA) with 0.1% Triton-X, 5.0% normal donkey serum, PBS, on a rotating shaker for
24 hours under refrigeration. Following primary incubation, tissue was washed for 15 minutes in
PBS and then incubated in secondary antibody (Alexaflour anti-rabbit 488 for Thr34/Thr75,
Alexflour anti-mouse 594 for ENK, Alexaflour anti-goat 594 for SP, 1:200, Life Scientific) with
0.1% Triton-X, 5.0% normal donkey serum, PBS, on a rotating shaker for 120 minutes.
Following secondary, tissue was washed for 15 minutes in PBS, wet mounted on untreated slides
and allowed to dry overnight. Slides were cover slipped with Prolong-Gold mounting medium
and allowed to dry overnight. Tissue was imaged on an Axio Imager-M2 fluorescence
microscope with FITC filter. All images used for counting cells were 20X magnification. Cells
were counted using a custom written macro for ImageJ.
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Microdialysis Probe Implantation Procedures:
Before surgery, rats were anesthetized with a 1.0 ml/kg i.p. injection of a cocktail
solution containing 10.0 ml of 100 mg/mL ketamine plus 0.75 ml of 20.0 mg/ml xylazine (both
from Phoenix Scientific, Inc., St. Joseph, MO, USA). Rats were placed in a stereotaxic frame
(Kopf, Tujunga, CA, USA) with the upper incisor bar 5.0 mm above the interaural line. The rats
received unilateral implantations of a 10.0 mm probe guide cannulae (Bioanalytical Systems
Inc., BAS, Indianapolis, IN, USA). The tips of the guide cannulae were implanted 2.0 mm above
nucleus accumbens core (AP: +2.8 mm, ML: ±1.4 mm, DV: −5.8 mm from bregma) and were
secured to the skull with stainless steel screws and cranioplastic cement. The guide cannula
implantations were counterbalanced within the group (left or right accumbens). Stainless steel
stylets were inserted into the guide cannulae to maintain patency of the cannulae until probe
insertion. Following surgery, all animals were housed in separate cages and allowed 7 days postsurgical recovery time.

DA Microdialysis and HPLC:
Animals were placed in Plexiglas chambers (28x28x23 cm3) for 8 hours, one day prior to
sampling, in order to habituate to sampling conditions. During this period, the probe was not
inserted, nor were the rats tethered to the rig. Infusion pumps were running in order to habituate
rats to the sound. The following day, rats were tethered and the probe was inserted. Artificial
cerebrospinal fluid (ACSF) was pumped through the probe at a rate of 2µl/min using a syringe
pump (Harvard Apparatus, Cambridge, MA). Two hours post-insertion, sampling began and
continued for 6 hours. Following the end of the sampling session, the probe was removed and all
animals were returned to home cages. Samples were frozen and analyzed for DA content using
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reverse-phase HPLC with electrochemical detection (ESA, New Bedford, MA, USA). The
electrochemical parameters were: channel 1: −100 mV, channel 2: +200 mV volts, and guard
cell: +350 mV. Each liter of mobile phase contains 27.6 g sodium phosphate monobasic
monohydrate, 8% methanol, 750 µL 0.1 M EDTA, and 2000 µL 0.4 M sodium octyl sulfate
(SOS) dissolved in dH2O (pH=4.5). Flow rate was 1.0 mL/min. DA standards were assayed
before, during, and after the collection of dialysis samples.

Statistical Analyses:
Total lever presses, highest ratio achieved, active lever time and chow consumption on
the PROG/chow were analyzed with repeated measures ANOVA. Non-orthogonal planned
comparisons (Keppel, 1991) were used to determine differences between each dose. To examine
differences between high and low performers, these variables were reanalyzed with repeated
measures factorial ANOVA where the between subjects variable was performance group.
Additionally, total lever presses under vehicle and 40.0 mg/kg conditions were analyzed between
high and low performers using analysis of simple effects. Mean DARPP-32 positive cells across
each region of interest were analyzed using repeated measures factorial ANOVA in which the
between subjects variable was treatment. Univariate ANOVA with post-hoc analysis (Tukey)
was used to determine differences between treatment levels within each region of interest.
Changes in neurochemical (DA) levels were calculated as percentage change from baseline, with
the mean of the two samples immediately preceding the lever-pressing session serving as the
100% baseline level. Animals that had a variability of more than 35% from the mean during the
two baseline samples were excluded from further analyses. A factorial ANOVA with repeated
measures on the time factor was used to test for differences in neurochemical changes.
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Experiment 1: The effects of Bupropion on PROG/chow performance
On test days, rats (n = 42, drug naïve) received injections of 10.0, 20.0, 40.0 mg/kg
bupropion or vehicle, 30 minutes prior to testing. This experiment employed a within-subjects
design, with each subject receiving all drug treatments, once per week, in a randomly varied
order.

Experiment 2: Effects of Bupropion on NAc DA in untrained rats as measured by in-vivo
microdialysis
On test days, rats (n=15) received injections of 20.0, 40.0 mg/kg bupropion or vehicle
following the second baseline sample.

Experiment 3: Effects of Bupropion on NAc DA in untrained rats as measured by pDARPP-32
immunoreactivity
On test days, rats (n=15) received injections of 20.0, 40.0 mg/kg bupropion or vehicle, 2
hours prior to being perfused for tissue analysis.

Results
Experiment 1: Bupropion increases PROG/chow responding
Repeated measures ANOVA revealed a significant effect of bupropion on total lever
presses (F[3,123] = 33.038, p < 0.001, Figure 5.1A). Planned comparisons demonstrated that
total lever presses were significantly increased at 20.0 and 40.0 mg/kg (p < 0.05). In order to
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analyze differences between high and low performers losers, repeated measures factorial
ANOVA was used. In this case, there was a significant effect of bupropion on total lever presses.
In addition, there was a significant effect of group (F[] = , p < 0.05). Moreover, there was a
significant treatment by group interaction in total lever presses (F[3,120] = 2.726, p < 0.05).
Bupropion also had a significant effect on highest ratio achieved (F[3,123] = 30.329, p <
0.001, Figure 5.1B). Highest ratio achieved was significantly increased at both 20.0 and 40.0
mg/kg doses (p < 0.05; planned comparisons). Repeated measures factorial ANOVA revealed a
significant effect of bupropion on highest ratio achieved. Furthermore, there was a significant
effect of group on highest ratio achieved (F[] = , p < 0.05). In addition, there was a significant
treatment by group interaction in highest ratio achieved (F[3,120] = 7.201, p < 0.05).
There was a significant effect of bupropion treatment on active lever time (F[3,123] =
47.423, p < 0.001, Figure 5.1C). Non-orthogonal planned comparisons revealed that active lever
time was significantly increased at 20.0 and 40.0 mg/kg doses (p < 0.05). Repeated measures
factorial ANOVA showed that there was a significant effect of bupropion on active lever time
(F[] = , p < 0.05). Moreover, there was a significant effect of group on active lever time (F[] = , p
< 0.05). Furthermore, there was a significant treatment by group interaction in active lever time
(F[3,120] = 7.038, p < 0.05).
Chow consumption also was significantly affected by bupropion (F[3,123] = 175.142, p <
0.001, Figure 5.1D). Planned comparisons demonstrated that chow consumption was
significantly decreased at 40.0 mg/kg compared to vehicle (p < 0.05). Repeated measures
factorial ANOVA revealed a significant effect of bupropion on chow consumption (F[] = , p <
0.05). Furthermore, there was a significant effect of group on chow consumption (F[] = , p <
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0.05). In addition, there was a significant treatment by group interaction in chow consumption
(F[3,120] = 7.904, p < 0.05).
In order to analyze differences between high and low performers, rats were split into two
performance groups (as in chapter 3) and reanalyzed with repeated measures factorial ANOVA
to determine any performance lever related differences in the effects of bupropion. There was a
significant treatment by group interactions for all four variables (total lever presses (F[3,120] =
2.726, p < 0.05), highest ratio achieved (F[3,120] = 7.201, p < 0.05), active lever time (F[3,120]
= 7.038, p < 0.05) and chow consumption (F[3,120] = 7.904, p < 0.05)). Based on these
findings, high performers and low performers were separated (as in chapter 3) and analyzed with
repeated measures ANOVA in order to explain interactions. Repeated measures ANOVA
revealed a significant effect of treatment in high performers on total lever presses (F[3,60] =
9.468, p < 0.05), highest ratio achieved (F[3,60] = 7.015, p < 0.05), active lever time (F[3,60] =
12.366, p < 0.05) and chow consumption (F[3,60] = 66.461, p < 0.05). Planned comparisons
demonstrated that total lever presses, highest ratio achieved and active lever time were all
increased at 20.0 and 40.0 mg/kg bupropion compared to vehicle (p < 0.05). Furthermore, chow
consumption was decreased in high performers at all doses compared to vehicle (p < 0.05).
Repeated measures ANOVA also showed a significant effect of treatment in low performers on
total lever presses (F[3,60] = 40.359, p < 0.05), highest ratio achieved (F[3,60] = 46.128, p <
0.05), active lever time (F[3,60] = 63.096), and chow consumption (F[3,60] = 160.489, p < 0.05).
Highest ratio achieved and active lever time were both significantly increased at 20.0 and 40.0
mg/kg bupropion compared to vehicle (p < 0.05; planned comparisons) whereas total lever
presses were only increased at 40.0 mg/kg compared to vehicle (p < 0.05). Furthermore, chow
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consumption in low performers was decreased at all doses of bupropion compared to vehicle (p <
0.05).
To further analyze interactions between groups on each measure, individual doses were
analyzed using univariate ANOVA with group as the fixed factor. ANOVA revealed that a major
source of the interaction in total lever presses was that low performers responded less than high
performers on vehicle (F[1,40] = 15.822, p < 0.05), 10.0 mg/kg (F[1,40] = 22.796, p < 0.05) and
20 mg/kg (F[1,40] = 33.295, p < 0.05), but did not differ from high performers at 40.0 mg/kg
(F[1,40] = 1.449, n.s.). Similarly, the interaction in highest ratio achieved was the result of low
performers reaching a lower ratio than high performers on vehicle (F[1,40] = 27.644, p < 0.05),
10.0 mg/kg (F[1,40] = 36.370, p < 0.05) and 20.0 mg/kg (F[1,40] = 39.729, p < 0.05), but were
not different from high performers on 40.0 mg/kg bupropion (F[1,40] = 0.274, n.s.). Moreover,
the interaction in active lever time can be explained by low performers showing less active lever
time on compared to high performers on vehicle (F[1,40] = 18.068, p < 0.05), 10.0 mg/kg
(F[1,40] = 16.628, p < 0.05), 20.0 mg/kg (F[1,40] = 25.698, p < 0.05), but no difference between
groups on 40.0 mg/kg bupropion (F[1,40] = 0.002, n.s.). Finally, the interaction in chow
consumption can be explained by low performers consuming significantly more chow compared
to high performers on vehicle (F[1,40] = 25.160, p < 0.05), 10.0 mg/kg (F[1,40] = 19.637, p <
0.05), 20.0 mg/kg (F[1,40] = 30.121, p < 0.05), but no difference between groups on 40.0 mg/kg
bupropion (F[1,40] = 0.162, n.s.). Moreover, these differences were supported by measures of
effect size in which low performers showed a greater effect of bupropion on total lever presses,
highest ratio achieved, active lever time and chow consumption compared to high performers
(See Table 5.1).
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Experiment 2: Bupropion increases extracellular DA in NAc Core in untrained animals
Repeated measures ANOVA revealed a significant effect of sample on extracellular DA
(F[7,91] = 7.883, p < 0.05, Figure 5.2). Non-orthogonal planned comparisons revealed that postdrug sample 2, 3, and 4 were all significantly different from BL2 (p < 0.05). Repeated measures
factorial ANOVA demonstrated a significant effect of sample (F[7,77] = 12.815, p < 0.05).
Furthermore, there was a significant sample by treatment interaction. Moreover, there was a
significant effect of treatment group (F[14,77] = 6.656, p < 0.05). In addition, there was a
significant effect of treatment group (F[2,11] = 7.978, p < 0.05). As a result, each treatment
group was analyzed separately with repeated measures ANOVA. There was no difference
between samples in vehicle treated rats (F[7,21] = 1.561, n.s.). There was a significant effect of
treatment in both 20.0 mg/kg (F[7,28] = 7.669, p < 0.05) and 40.0 mg/kg treated rats (F[7,28] =
10.657, p < 0.05). Non-orthogonal planned comparisons revealed that only post-drug sample 2
was significantly different from BL2 in rats treated with 20.0 mg/kg bupropion (p<0.05).
Planned comparisons demonstrated that post-drug samples 2, 3, 4 and 5 were all significantly
different from BL2 in rats treated with 40.0 mg/kg bupropion (p<0.05).

Experiment 3: Bupropion increases phosphorylated DARPP-32 expression at both Thr34 and
Thr75 residues
Factorial ANOVA with repeated measures on the brain region variable revealed a
significant difference in pDARPP-32(Thr34) immunoreactivity across regions studied (F[2,24] =
3.854, p < 0.05). Furthermore, there was a significant effect of treatment group (F[2,12] =
37.046, p < 0.05, Figure 5.3A). However, there was no treatment group by region interaction
(F[4,24] = 2.334, n.s.). Univariate ANOVA revealed a significant effect of treatment on Thr34
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expression in accumbens core (F[2,12] = 22.093, p < 0.05), shell (F[2,12] = 12.862, p < 0.05)
and dorsal striatum (F[2,12] = 39.989, p < 0.05). Post hoc analysis (Tukey) revealed that Thr34
expression in the accumbens core was significantly increased at 20.0 and 40.0 mg/kg (p < 0.05)
compared to vehicle. These doses did not significantly differ from each other however. In the
accumbens shell and dorsal striatum, only 40.0 mg/kg bupropion increased Thr34 expression
over vehicle (p < 0.05).
Repeated measures factorial ANOVA revealed that there was no significant difference
across regions in pDARPP-32(Thr75) immunoreactivity (F[2,24] = 0.559, n.s.), nor was there a
significant treatment group by region interaction (F[4,24] = 2.088, n.s.). However, there was a
significant effect of treatment group on Thr75 expression (F[2,12] = 5.961, p < 0.05, Figure
5.3B). Univariate ANOVA revealed a significant effect of treatment on Thr75 expression in
accumbens core (F[2,12] = 4.191, p < 0.05), shell (F[2,12] = 4.343, p < 0.05) and dorsal striatum
(F[2,12] = 5.473, p < 0.05). Post hoc analysis (Tukey) demonstrated that Thr75 expression in
accumbens core, shell, and dorsal striatum was significantly increased by 40.0 mg/kg bupropion
(p < 0.05).

Table 1: Bupropion Effect Size – High Performers vs. Low Performers. Expressed as partial eta2.
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Figure 5.1: Bupropion increases PROG/chow responding. Mean (+SEM) total lever presses (A),
highest ratio achieved (B), active lever time (C), and chow consumption (D). (* p < 0.05,
different from vehicle).
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Figure 5.2: High Responder / Low Responder Breakdown: Bupropion showed a greater effect on
low performers compared to high performers. In low performers, total lever presses (A), highest
ratio achieved (B) and active lever time (C) were all increased to equal high performers at the
highest dose (40.0 mg/kg). Furthermore, chow consumption in high and low performers was
equal at the highest dose (40.0 mg/kg). (* p < 0.05, different from low responders)
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Figure 5.3: Bupropion increases extracellular DA in NAc core. Mean (+ SEM) extracellular DA
(expressed as percent baseline) in 30-minute samples. 2 baseline samples were collected prior to
injection of vehicle or bupropion. 6 Samples were collected following injection. (* p < 0.05,
different from baseline).
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Figure 5.4: Bupropion increases expression of DARPP-32 at both Thr34 and Thr75 subunits. A)
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treatment group. B) Mean (+ SEM) DARPP-32-Thr75 positive cells counted in each region of
interest for each treatment group. (* p < 0.05, different from vehicle)
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Figure 5.5: Photomicrographs of pDARPP-32(Thr34)(A) and pDARPP-32(Thr75)(B) staining in
each region of interest, showing representative vehicle treated (left column) and rats treated with
40 mg/kg bupropion (right column). All images were taken at 20X magnification.
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Chapter 6: Discussion

Summary of Experiments
The present work was conducted to assess a novel PROG/Chow feeding choice procedure
for its utility in modeling the effort-related motivational symptoms of depression. These studies
examined the effects of numerous manipulations, including blockade or depletion of DA, and the
ability of both well characterized and putative antidepressants to reverse these effects. Moreover,
these studies assessed whether or not Flinders Sensitive line (FSL) rats demonstrated clear effortrelated deficits on the PROG/chow compared to controls. Finally, this work examined the
behavioral and neurochemical effects of the common antidepressant bupropion, employing the
PROG/Chow feeding choice task in order to assess differences in drug effects between high and
low performers.

Chapter 2 Discussion
The experiments in chapter 2 investigated the effects of several manipulations using a
concurrent PROG/chow feeding task. Experiment 1 demonstrated that the DA D2 antagonist
haloperidol decreased number of lever presses, maximum ratio achieved, and active lever time
(i.e., the time the PROG schedule was active). These findings are consistent with previous
studies showing the ability of DA antagonists or accumbens DA depletions to reduce foodreinforced lever pressing in animals responding on the concurrent FR5/choice task (Salamone et
al., 1991, 2002; Sink et al., 2008), as well as conventional operant schedules, including various
versions of the progressive ratio schedule (Aberman et al., 1998; Hamill et al. 1999). Despite
producing clear reductions in measures of operant responding, haloperidol did not decrease chow
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intake, which indicates that primary food motivation was intact in haloperidol-treated rats.
Moreover, previous studies have shown that 0.1 mg/kg haloperidol does not change preference
for these specific high carbohydrate food pellets relative to chow, or reduce total intake of either
food type in free-feeding tests (Salamone et al. 1990, 1991). In fact, there was a slight tendency
for some rats to show increased chow intake after haloperidol treatment, which was marked by
the significant correlation between vehicle lever pressing and the difference in chow intake
between vehicle and the highest dose of haloperidol. In other words, animals that were high
lever press responders under the vehicle condition, and therefore had correspondingly low levels
of chow intake, showed greater increases in chow consumption on haloperidol than low
responders did. In fact, the 4 rats with the highest level of lever pressing showed very substantial
increases in chow intake after haloperidol injection (i.e., increases of 3-6 grams relative to
vehicle). Nevertheless, unlike the previous experiments using the FR5/chow choice task
(Salamone et al. 1991, 2002; Sink et al. 2008), haloperidol did not produce an overall significant
increase in chow intake. One possible explanation for this pattern is the different levels of chow
intake with the two procedures. With the FR5/chow choice procedure, baseline or control levels
of lever pressing are relatively high, while chow intake is relatively low (i.e., 1-2 grams), making
it possible to observe an increase in chow intake with administration of a DA antagonist. In
contrast, baseline or control levels of chow intake are much higher with the PROG/chow choice
procedure (i.e., 7-8 grams), and are near ceiling levels of chow intake for a 30 minute period
without water being available. For example, Randall et al. (2010) demonstrated that foodrestricted rats in a free feeding study consume approximately 8 grams of chow in a 30-minute
period. Thus, with the PROG/chow choice procedure, it is difficult to observe drug-induced
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increases in chow intake in animals that are already eating chow at maximal or near maximal
levels.
The adenosine A2A antagonist MSX-3 produced effects that were opposite to those of
haloperidol; MSX-3 increased number of lever presses and maximum ratio achieved, and also
increased the amount of time that animals kept the lever active during the session. This is
consistent with previous work showing that adenosine A2A antagonists have stimulant-like
properties. For example, the adenosine A2A antagonists MSX-3 and istradefylline increased lever
pressing on a fixed interval 4-minute schedule, which generates a relatively low baseline rate of
responding (Randall et al., 2011). In addition, the PROG/chow feeding choice procedure
allowed for parallel assessment of food intake, and MSX-3 decreased chow consumption at the
highest dose. Interestingly, although MSX-3 and haloperidol produced opposite effects on
measures of PROG lever pressing and chow intake, in both experiments, the reciprocal relation
between lever pressing and chow intake was preserved, as indicated by the high negative
correlations between lever pressing and chow intake across all treatments (-0.76 and -0.78). This
inverse correlation between lever pressing and chow intake has been reported in previous
experiments studying the effects of DA antagonists or depletions on FR5/chow feeding choice
performance (Cousins et al. 1993; Salamone et al. 2002; Sink et al. 2008).
Experiment 3 was conducted to determine the effect of appetite-related manipulations on
PROG/chow feeding choice performance, in order to provide a contrast with the effects of
haloperidol. Two different appetite manipulations were employed: pre-feeding, and
administration of a cannabinoid CB1 receptor antagonist/inverse agonist. Pre-feeding animals
prior to their test session, which was used to reduce food motivation and thereby devalue the
food reinforcement (Salamone et al. 1990; Aberman and Salamone 1999), produced marked
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decreases in number of lever presses and highest ratio achieved. But, unlike the effects of
haloperidol, pre-feeding also substantially reduced chow consumption. In experiment 3b, the
CB1 receptor antagonist/inverse agonist AM251 was assessed. CB1 antagonists/inverse agonists
are putative appetite suppressant drugs that have been shown to decrease food intake in animals
(Colombo et al., 1998; McLaughlin et al., 2003; Sink et al., 2008, Randall et al., 2010) and
humans (Pi-Sunyer et al., 2006). On the PROG/chow feeding choice task, AM251 decreased
number of lever presses, maximum ratio achieved, and chow consumption. Thus, the pattern of
effects on lever pressing and chow intake produced by pre-feeding and AM251 differed
markedly from those produced by haloperidol. Moreover, while there was a high inverse
correlation between lever pressing and chow intake in the haloperidol experiment, there were no
significant correlations between these measures in the pre-feeding and AM251 experiments.
This analysis shows that the inverse relation between lever pressing and chow intake, which is
evident under baseline conditions and also throughout the haloperidol experiment, is not shown
when primary food motivation is reduced by pre-feeding or drugs, because appetite-suppressant
manipulations decrease both food reinforced lever pressing and chow consumption (Salamone et
al. 2002; Sink et al. 2008). Although there are a number of factors that can influence progressive
ratio performance (e.g. Arnold and Roberts, 2007), the present results demonstrate that it is
exceedingly unlikely that haloperidol is decreasing PROG lever pressing because of a reduction
in primary food motivation or the unconditioned reinforcing properties of food. Clearly, in the
absence of parallel measures of food intake, or taste reactivity (e.g. Smith et al. 2011),
progressive ratio break points should not be used as markers of food “reward”, or “hedonic”
reactivity to food.
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An important aspect of the PROG/chow procedure is that performance is characterized by
substantial individual variability. While some rats lever pressed relatively little and had high
levels of chow intake, others lever pressed much more and ate relatively little chow. Experiment
4 employed pDARPP-32-(Thr34) immunohistochemistry to determine if there were
neurochemical differences between high responders and low responders. The entire group of
animals was divided in two by a median split based upon numbers of lever presses, and
pDARPP-32(Thr34) expression was determined. High responders did not differ from low
responders in terms of pDARPP-32(Thr34) expression in CG1 or CG2 regions of anterior
cingulate cortex, or in accumbens shell. However, high responders did show greater pDARPP32(Thr34) expression in accumbens core than low responders. pDARPP-32(Thr34)
immunoreactivity was used to provide a marker of signal transduction activity, and evidence
indicates that DA acting through the D1 receptor and the G proteins (Gs/Golf) activates adenylate
cyclase activity, thereby stimulating PKA-mediated phosphorylation of DARPP-32 at the Thr34
site (Nishi et al. 2000; Kuroiwa et al. 2008; Bateup et al. 2008; Yger and Girault 2011).
DARPP-32 expression has been used to study drug effects (Bateup et al. 2008; Yger and Girault
2011), and a few studies have focused on changes in DARPP-32 immunoreactivity associated
with behavioral manipulations. Danielli et al. (2010) demonstrated that pDARPP-32(Thr34)
showed increased expression in nucleus accumbens shell after the first exposure to a novel food.
Recently, Segovia et al. (2012) reported that pDARPP-32(Thr34) expression in accumbens shell
and core was increased in animals undergoing FR5 operant training. Although several
neurochemical factors can influence pDARPP-32(Thr34) production (Yger and Girault 2011), it
is reasonable to suggest that the higher level of pDARPP-32(Thr34) expression in high
responders relative to low responders could reflect greater DA transmission in the animals
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working harder on the lever pressing component of the task (Segovia et al. 2011, 2012). If so,
this could indicate that individual differences in work output are related to increased DA
transmission in striatal areas, as recently shown in a human imaging study (Treadway et al.
2012). Furthermore, these observations of individual variability in exertion of physical effort are
consistent with recent studies of individual variability in cognitive effort across subjects (i.e.,
“workers” vs. “slackers”, Cocker et al. 2012).
In summary, the DA antagonist haloperidol reduced the number of lever presses and
highest ratio achieved but did not suppress chow intake. In contrast, the adenosine A2A
antagonist MSX-3 increased lever presses and highest ratio achieved, but decreased chow
consumption. Pre-feeding and administration of the cannabinoid CB1 antagonist/inverse agonist
AM251 decreased lever presses, highest ratio achieved, and chow intake. Including the option of
having chow concurrently available allows one to conclude that the effects of DA antagonism
differed greatly from those produced by pre-feeding or decreases in CB1 transmission, despite
the fact that all three manipulations decreased lever pressing. Thus, haloperidol is not reducing
PROG responding because of a general reduction in the valuation of food motivation or
reinforcement. Instead, the present data are consistent with the hypothesis that haloperidol left
aspects of food motivation intact, but reduced the tendency to work for food reinforcement.
Furthermore, DA-related signal transduction activity (pDARPP-32(Thr34) expression) was
greater in high responders (i.e., rats with high lever pressing output) compared to low responders,
indicating that accumbens core signal transduction activity is related to individual differences in
work output. Future studies should compare the effects of DA D1 and D2 antagonists, and
should determine if adenosine A2A antagonism is capable of reversing the effects of DA
antagonism. Studies comparing cannabinoid CB1 inverse agonists with neutral antagonists (e.g.
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Sink et al. 2008; Randall et al. 2010) would be useful for further exploration of the role of CB1
receptor signaling in performance on this procedure. Finally, additional neurochemical measures
should be investigated for their possible relation to lever pressing output on this task, including
microdialysis studies of DA release (Segovia et al. 2011), and other markers of signal
transduction activity (e.g. c-Fos, pDARPP-32(Thr75)) in different striatal cell types (e.g.
encephalin or substance P positive neurons; Segovia et al. 2012). These studies are important for
understanding activational aspects of motivation, and may contribute to our understanding of the
neural basis of effort-related motivational impairments (e.g. anergia, psychomotor retardation,
fatigue) in depression and other disorders (Salamone et al. 2006, 2007, 2012).

Chapter 3 Discussion
The studies in chapter 3 examined the effects of the VMAT-2 inhibitor and DA depleting
agent TBZ on the PROG/chow feeding choice task. TBZ significantly decreased total lever
presses, highest ratio achieved and active lever time. In addition, TBZ did not produce an overall
significant effect on chow intake, indicating that appetite for chow consumption was not
suppressed at the doses tested. These effects of TBZ are consistent with those previously
demonstrated in rats assessed on the FR5/chow task (i.e., decreased lever pressing and increased
chow intake after TBZ administration; Nunes et al., submitted). Moreover, Nunes et al.
(submitted) reported that doses of TBZ up to 1.0 mg/kg had no effect on consumption of operant
pellets or lab chow, and did not alter preference of pellets over chow. Thus, it seems unlikely
that the present results with TBZ occurred because of a change in food preference.
Importantly, these effects were more pronounced in high performers. High performers
showed decreases in total lever presses at 0.5 mg/kg TBZ whereas low performers required
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0.75mg/kg in order to show decreases in total lever presses. Moreover, high performers showed
decreases in highest ratio achieved and active lever time at all doses of TBZ tested whereas low
performers showed no changes in highest ratio achieved or active lever time under any dose of
TBZ. In addition, high performers showed increases in chow consumption at 0.5, 0.75 and 1.0
mg/kg TBZ, where low performers showed no change in chow consumption, presumably
because they were already consuming chow at near ceiling levels.
Previous work has shown that, in the dose range tested in Chapter 2, TBZ significantly
decreased extracellular DA in nucleus accumbens as measured by microdialysis (Nunes et al.,
submitted). In addition, TBZ affected pDARPP-32 expression in a manner consistent with
reduction of DA transmission at both D1 and D2 family receptors. Thus, the present
experiments also studied the effects of highly selective D1 and D2 antagonists. Selective D1 or
D2 antagonism (via administration of ecopipam or eticlopride, respectively) demonstrated
similar effects to TBZ on the PROG/chow feeding task, decreasing total lever presses, highest
ratio achieved and active lever time. Similar to TBZ, these effects were more pronounced in high
performers. Thus, it appears that reductions in DA transmission at both D1 and D2 receptors
contribute to the effects induced by TBZ.
In contrast, the effects observed with DA blockade or depletion differs from those
induced by appetite manipulation, as demonstrated by the effects of the cannabinoid CB1 neutral
antagonist and putative appetite suppressant AM4113. The effects of AM4113 observed in
Chapter 3 were similar to those observed for the CB1 inverse agonist AM251 in Chapter 2; total
lever presses, highest ratio achieved and chow consumption all decrease, consistent with
previous studies using CB1 inverse agonists (Sink et al., 2008; Randall et al., 2012). This further
supports previous findings that, unlike manipulations of appetite, low doses of DA antagonists or
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DA depleting agents, as well as local interference with DA transmission in nucleus accumbens,
do not alter effort-related choice because of a general decrease in primary food motivation
(Salamone et al., 2002; Sink et al., 2008; Randall et al., 2012; Nunes et al., submitted). In
addition, AM4113 produced greater effects on lever pressing in high performers compared to
low responders. Specifically, high performers showed decreases in total lever presses and highest
ratio achieved, whereas low performers showed no change in total lever presses. This pattern of
effects in low performers is likely due to the fact that these animals get the vast majority of their
food from chow intake. The overall similarity between the actions of a CB1 neutral antagonist
(AM4113) and a CB1 inverse agonist (AM251) suggests that there is endogenous cannabinoid
tone regulating food motivated behavior, which is attenuated by occupation of CB1 receptors by
the neutral antagonist (Sink et al. 2008).
In recent years, there has been increasing interest in the use of adenosine A2A antagonists
for their potential antidepressant effects (Salamone, 2007). This is supported by studies using
traditional animal models of depression including the forced swim and the tail suspension tests
where adenosine A2A antagonists have been shown to increase swim and struggle time (Hodgson
et al. 2009; Hanff et al. 2010). Moreover, several studies have demonstrated the ability of A2A
antagonists to reverse the effects of selective DA antagonism on a variety of effort-related tasks
including the FR5/chow feeding choice task and the T-Maze barrier task (Mott et al., 2009;
Farrar et al., 2010; Nunes et al., 2011). In the present studies, the adenosine A2A antagonist
MSX-3 was capable of reversing the effects of TBZ, increasing total lever presses, highest ratio
achieved and active lever time. These effects are consistent with TBZ/MSX-3 reversal studies
conducted in rats tested on the FR5/Chow procedure (Nunes et al., submitted). Moreover, these
results are consistent with studies demonstrating the minor-stimulant properties of adenosine A2A
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antagonists including MSX-3 (Randall et al., 2011, 2012). In the present studies, the reversal
effects produced by MSX-3 were more pronounced in high performers, in which MSX-3 plus
TBZ increased total lever presses, highest ratio achieved and active lever time relative to TBZ
alone. Low performers on the other hand showed no effect of treatment. It is likely that this
pattern of effects is due to the fact that the TBZ effects on PROG performance are greater in high
performers, which could render them more susceptible to reversal.
In addition to assessing putative antidepressants, it is equally as important to assess well
characterized antidepressants on the PROG/chow feeding choice paradigm, in order to validate
that it can be used for the assessment of this class of drugs. Because TBZ depletes DA, a logical
point of focus was on an antidepressant that works on DA, such as bupropion. Moreover,
bupropion is one of the most widely prescribed antidepressants, and it is one of the few
antidepressants that has shown efficacy in treating the energy-related symptoms such as fatigue
and psychomotor slowing in patients with depression and related disorders (Stahl 2002;
Demyttenaere et al. 2005; Papakostas et al., 2006; Pae et al. 2007). In the current experiments,
bupropion was capable of reversing the effects of TBZ on the PROG/chow procedure, increasing
total lever presses, highest ratio achieved and active lever time. Moreover, at the highest dose
(15.0 mg/kg) it decreased chow consumption compared to TBZ treated animals. While both high
performers and low performers showed increases in total lever presses, highest ratio achieved
and active lever time following administration of bupropion, the most marked change was the
decrease in chow consumption in high performers. These results are consistent with previous
findings on the FR5/Chow procedure (Nunes et al., submitted) and the T-Maze barrier task
(Yohn et al., IN PREP), which also demonstrated the ability of bupropion to reverse the effects
of DA depletion.
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In addition to compounds that block DA uptake such as bupropion, there has been
interest in compounds that block the enzymatic breakdown of DA for their antidepressant effects.
MAO inhibitors are one group of compounds that have been assessed for their antidepressant
effects. Originally developed as an antiparkinsonian drug (Riederer and Laux, 2011), the MAOB inhibitor deprenyl has been shown to have antidepressant effects in humans (Jang et al. 2013;
Sclar et al. 2013), as well as rodents tested on traditional animal models of depression, including
the forced swim test and inescapable shock paradigm (Martin et al., 1987, Shulz et al., 2010). In
view of the fact that nonselective MAO inhibitors have been used as antidepressants, and
deprenyl and related drugs are recommended for treating akinesia and psychomotor slowing seen
in Parkinson’s disease, it is reasonable to hypothesize that an MAO-B inhibitor could be useful
for the treatment of psychomotor slowing and fatigue observed in depressed patients. The current
studies assessed the ability of deprenyl to reverse the effects of TBZ on the PROG/Chow
procedure. Deprenyl was capable of reversing these effects, increasing total lever presses,
highest ratio achieved and active lever time. In addition, deprenyl produced a decrease in chow
consumption at the highest dose (10.0 mg/kg) compared to TBZ alone. In analyzing these results
by performance level, it was revealed that these effects were greater in high performers who
demonstrated significant increases in total lever presses, highest ratio achieved and active lever
time whereas low performers showed little to no effect of deprenyl. As discussed above, this
could be due in part to the fact that TBZ produces greater effects in high performers, and
therefore they are easier to reverse.
Another group of drugs that act to block the enzymatic breakdown of DA, and thus could
have antidepressant effects are COMT inhibitors. There is clinical evidence of increased COMT
levels in depressed patients (Shulman et al., 1978). Moreover, there is evidence for genetic
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variations in the COMT gene that could lead to abnormal COMT function (Aberg et al., 2011).
The COMT inhibitor tolcapone has been used clinically in Parkinson’s patients to effectively
treat their effort-related depressive symptoms (Fava et al., 1999). The current studies sought to
assess tolcapone for its ability to reverse the effort-related impairments induced by TBZ on the
PROG/chow task. As described above, tolcapone failed to reverse the effects of TBZ on any
measure of PROG/chow performance in the dose range tested. One explanation for this lack of
effect comes from clinical studies demonstrating that improvements in energy-related symptoms
following tolcapone treatment in Parkinson’s patients were in the presence of LDOPA/carbidopa treatment (Fung et al., 2009). This suggests that tolcapone may be more
effective at reversing the effects of TBZ if it is co-administered with other drugs that stimulate
DA transmission, such as L-DOPA or bupropion. In addition, it has been suggested that COMT
plays a more important role in prefrontal cortex, where the dopamine transporter (DAT) is
sparse, compared to striatum, where DAT is abundant; such a pattern has been interpreted to
mean that COMT exerts a greater effect on prefrontal cortex DA metabolism, while MAO exerts
a greater effects on striatal DA metabolism (Karoum et al., 1994; Matsumoto et al., 2003).
Furthermore, there is evidence from COMT knockout mice showing that COMT has little effect,
if any, on striatal DA levels (Yavich et al., 2007). When you consider these findings in the
context of other clinical studies demonstrating that entacapone, a peripherally restricted COMT
inhibitor, has also been shown to be effective at treating these symptoms when co-administered
with L-DOPA (Moreau et al., 1994, Muller et al., 2009), it seems possible that the antidepressant
effects of COMT inhibition are due to blockade of peripheral breakdown of L-DOPA, increasing
the amount that reaches the CNS. In fact, L-DOPA has been shown to improve effort-related
symptoms in depressed patients (Brown and Gerson, 1993).
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Chapter 4 Discussion
Since the late 1970’s, it has been suggested that the Flinders Sensitive line rats could be
used to model depression (Overstreet et al., 1979, 2005, 2013). This was largely due to evidence
that FSL rats share some characteristics with depressed patients, including cholinergic sensitivity
(Overstreet et al., 1979; Janowski et al., 1980), evidence of psychomotor slowing (Overstreet and
Russel, 1986, Bushnell et al., 1995), disrupted sleep cycles (Overstreet and Russell, 1986),
anxiety (Overstreet et al., 1990) and digestive difficulties (Djuric et al., 1995). Moreover, these
rats demonstrate depressive behavioral characteristics in traditional rodent models of depression,
such as the forced swim test and inescapable shock paradigm (Overstreet et al., 1986). Until the
current studies, FSL rats had never been assessed for deficits in effort-related decision making,
or performance of a wide variety of food-motivated behaviors, compared to normal SpragueDawley controls. Therefore, the goal of the current experiments was to make such an
assessment.
It was hypothesized that food restricted FSL rats would perform normally on the FR1 and
progressive ratio alone, but would show reduced lever pressing and increased chow consumption
on the PROG/chow procedure compared to controls. This was in part based on evidence that FSL
rats have been reported to show reduced operant responding on some schedules (Overstreet et al.,
1986; Bushnell et al., 1995). In fact, FSL rats showed a mixed pattern of results across the
various tasks used, which did not indicate a clear alteration in effort-related choice behavior. FSL
rats showed reduced responding when tested on the FR1, PROG alone, and FR20 schedules.
However, when tested on the PROG/chow feeding choice task, there was no significant
alteration in lever pressing, though there was a deficit in chow consumption. In other words,
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FSL rats did not show the same pattern of effort-related effects demonstrated by rats treated with
DA antagonists or TBZ (Chapters 2 and 3), or by depressed patients (Treadway et al. 2012).
Instead, they showed a pattern of effects that more closely resembled the CB1 inverse agonist
AM251 and the CB1 neutral antagonist AM4113. This pattern suggests that FSL rats show some
degree of appetite suppression, which makes it difficult to discern a clear alteration in effortrelated choice.
In order to assess food motivation in FSL rats to a greater degree, numerous free-feeding
probe trials were conducted. The first two probe trials assessed only Bio-serv pellet
consumption. While the first probe did not show a significant difference between groups, the
second trial (1 week later) revealed that FSL rats were consuming significantly fewer pellets
compared to controls. It is also important to note that the first probe trial showed a trend towards
an effect, and that the lack of effect could have been due to neophobia for the feeding chamber,
which limited intake in both FSL rats and controls. Following the pellet probes, a pellet
preference probe was conducted to determine if there was a difference in preference for pellets
versus lab chow in FSL rats compared to controls. On this probe, FSL rats showed a reduced
consumption of the high carbohydrate pellets, as well as a partially reduced preference for pellets
(relative to total grams of food intake) compared to control animals. The final probe trial
assessed lab chow consumption. Similar to the other trials, FSL rats consumed less lab chow
compared to controls. These findings further illustrate that FSL rats demonstrate appetite-related
deficits compared to controls.
There are several possible explanations for these appetite related effects. Cousins et al.
(1994) demonstrated that systemic administration of the muscarinic agonist pilocarpine
significantly reduced lever pressing on the FR5/chow task but failed to increase chow

	
  

105

consumption. This effect looks very similar to the effects seen with appetite suppressing
compounds and pre-feeding on this procedure (Salamone et al., 1991; Salamone et al., 2002,
Sink et al., 2008), and thus the pattern of effects seen in FSL animals could be reflective of their
cholinergic hypersensitivity. In addition, there is evidence that FSL rats show intestinal
discomfort, potentially linked to their cholinergic sensitivity, that could lead to decreased food
intake (Djuric et al., 1995). Consequently, it is possible that the cholinergic sensitivity observed
in FSL rats produces effects on appetite. This is consistent with the findings our findings on freefeeding probe trials and reduced lever pressing observed in CRF training.
Many depressed patients experience co-morbid anxiety. Moreover, increased anxiety
response has been observed in genetic animal models of depression, including the Wistar Kyoto
rats (O’Mahony et al. 2011). Previous studies focusing on anxiety-related behaviors in FSL rats
have generated mixed results. Although some studies have reported that FSL rats do not readily
display signs of anxiety (Overstreet et al., 2005), FSL rats have been shown to perform poorly in
on an active-avoidance task or in social interaction tasks (Overstreet et al., 1990, Overstreet et
al., 1994). The current findings failed to observe signs of anxiety in FSL rats, and in fact showed
the opposite effect. Results from the open field arena demonstrated that FSL rats actually showed
more inner crossings than controls, and they showed more inner crossings relative to total
crossings than controls. We observed similar behavior with the elevated plus maze, in which FSL
rats showed more open-arm entrances compared to controls. They also displayed more relative
open arm entries compared to controls. Furthermore, FSL rats spent more time in the open arms,
make more trips to the end of open arms and perform significantly more head dips compared to
controls. Taken together, these findings suggest that the FSL rats do not appear to show

	
  

106

increased anxiety over controls based on these traditional anxiety assessments. To the contrary,
they appear to be less anxious than control rats, as measured by the tests used.
In the FR20 experiment, FSL rats showed lower levels of lever pressing. Furthermore,
when analyzing local rates of responding via IRT’s, controls make significantly more fast
responses (responses occurring <250ms apart) than FSL rats. Moreover, FSL rats show
significantly more pauses (responses occurring >5 seconds apart) during the session compared to
controls. It is possible that this pattern represents some type of motor slowing. However, in
other tasks that measured motor activity (open field and elevated plus maze), FSL rats did not
show reductions in motor activity. Another possible explanation for these decreases is fatigue
related to poor respiration. Djuric et al. (1998) observed that FSL rats show reduced respiratory
function, which could lead to more rapid fatigue, especially on tasks with a higher work
requirement such as FR20.
While one cannot discount the shared characteristics between depressed patients and FSL
rats, the current studies show that there is not clear evidence of effort-related impairments in
these rats. While it is possible that an effort-related deficit is present, it is overshadowed by the
reduction in appetite observed in FSL rats. Furthermore, using the FSL as a model of depression
on the basis of appetite is somewhat misleading, as the role of appetite in depression is
complicated. While some depressed people show reduced appetite and weight loss, others show
the opposite (Lee et al. 1985). Moreover, FSL rats display behavior that bears considerable
similarity to rats treated with appetite suppressing compounds, such as CB1 inverse agonists and
antagonists.
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Chapter 5 Discussion
Bupropion is a catecholamine uptake inhibitor that has been of interest for many years for
the treatment of depression. Bupropion (Wellbutrin) is frequently prescribed, and in 2010, it was
reported to the most commonly prescribed antidepressant in the US (Milea et al. 2010).
Moreover, this drug is of particular interest because of evidence indicating that inhibition of DA
uptake may be a relatively effective treatment for the fatigue or psychomotor symptoms
observed in many depressed patients (Rampello et al. 1991; Stahl 2002; Demyttenaere et al.
2005; Pae et al. 2007). The goal of these experiments was to further investigate the behavioral
and neurochemical effects of bupropion.
In chapter 3, bupropion was shown to be capable of reversing the effort-related
impairments induced by TBZ. To expand on this finding, the first experiment in chapter 5
assessed the effects of bupropion on the PROG/chow procedure when administered on its own.
Bupropion produced marked increases in all measures of lever pressing (total lever presses,
highest ratio achieved, and active lever time) while producing decreases in chow consumption.
The significant interaction in total lever presses between performance groups was due to the fact
that that the effect on high performers was smaller than that shown by the low performers (see
Chapter 5, Table 1). Moreover, at 40.0 mg/kg bupropion, there were no significant differences
between high and low performers, indicating that bupropion made the two performance groups
roughly equal. This finding adds support to the utility of the PROG/chow procedure as a model
for assessing the effort-related symptoms of depression.
To better understand the effects of bupropion on DA signaling, two different
neurochemical measures were employed. The first set of experiments assessed the effects of
bupropion on extracellular DA concentrations within the nucleus accumbens core using
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microdialysis. Bupropion significantly increased extracellular DA at both 20.0 mg/kg and 40.0
mg/kg. Furthermore, these increases were observed during the same time span that an operant
session would be taking place (30-60 minutes post injection) supporting the findings of the
PROG/chow dose response experiment. This finding is consistent with previous findings
demonstrating the ability of bupropion to reverse the effects of TBZ and microdialysis studies
showing that TBZ decreases extracellular DA (Nunes et al., submitted).
The third set of experiments in this chapter assessed the effects of bupropion on DARPP32 immunoreactivity within the nucleus accumbens and dorsal striatum. Similar to the
microdialysis study above, the greatest effects were seen at 40.0 mg/kg. This was true for both
phosphorylated forms of DARPP (i.e., at the Thr34 and Thr75 amino acid residues), although the
magnitude of effects on Thr75 were smaller. Based upon the microdialysis results showing
increased extracellular DA after bupropion administration, and on the literature describing the
role of DARPP-32 as a signaling protein in striatal tissue (Svenningson et al. 2004; Bateup et al.
2008; Segovia et al. 2012), it is likely that pDARPP-32(Thr34) increased after bupropion
administration because of increased D1 receptor stimulation in substance P positive neurons,
while pDARPP-32(Thr75) increased because of increased D2 receptor stimulation in enkephalin
positive neurons. Thus, it appears that the doses of bupropion used in the present experiment
increased DA transmission at both “direct pathway” neurons that express D1 receptors, and
“indirect pathway” neurons that express D2 receptors. However, double-labeling methods would
be necessary to confirm that.
Taken together, these findings demonstrate that bupropion is capable of improving
performance in low responders, bringing them up to the level of high responders. This has
important implications in the study and possible treatment of the effort-related motivational
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impairments seen in depressed patients. Importantly, SSRI’s show little efficacy in treating these
symptoms. On the other hand, the current studies demonstrate that drugs like bupropion, which
affect DA signaling, are capable of improving these symptoms (Rampello et al. 1991; Brown and
Gershon, 1993; Pae et al. 2007). However, it is important to reiterate that bupropion is a
catecholamine uptake inhibitor, meaning that it also has effects on norepinephrine (NE). The
current work cannot rule out the potential effects of NE uptake inhibition on these types of
behaviors. For this reason, future work should also focus on the role of NE in these types of
behaviors and whether or not antagonism of NE produces these types of behavioral deficits.

General Discussion and Conclusions
All of the work discussed above provides important information about the utility of the
PROG/chow feeding choice procedure as a behavioral model of the effort-related motivational
symptoms of depression. Furthermore, because of the large amount of individual variability
produced by the PROG/chow feeding task, it is particularly useful for examining the individual
differences in drug effects between high and low performers. For example, bupropion produced a
greater relative increase in lever pressing in low performers compared to high performers. In
contrast, TBZ produced a greater relative decrease in total lever presses in high performers
compared to low performers. Another important advantage of this procedure is that it can be bidirectionally modulated by pharmacological manipulations. This is due to higher baseline chow
consumption observed on this procedure compared to the FR5/chow procedure, and the fact that
most rats do not spend the entire session lever pressing. Moreover, the PROG/chow feeding
choice procedure appears to be useful not only for studying effort-related impairments, but also
for the study of appetite-related manipulations.
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In developing animal models of any disorder, it is important to move beyond the
traditional diagnostic categories and assess the brain circuits related to specific symptoms, or sets
of symptoms. The FSL has been offered as a rodent model of depression since the 1980’s
(Overstreet et al., 2013), however, the current studies demonstrate that such a label could be
overgeneralizing the utility of the strain. FSL rats have been shown to be useful in screening
antidepressant compounds on tests of the mood related symptoms of depression. The current
studies clearly demonstrate however that these rats are not very useful when studying the effortrelated impairments reported by so many depressed patients. Instead, these rats appear to show a
general appetite-related deficit as demonstrated by several feeding probe trials and poor CRF
performance. Furthermore, they do not appear to demonstrate the co-morbid anxiogenic
symptoms that are seen in many depressed patients. With this in mind, researchers should be
cautious in the way strains are labeled and how complex disorders are studied. As was stated
earlier, there is no “one size fits all” treatment for depression, and as such, there likely is no such
all-inclusive animal model.
With focus shifting towards the effort-related symptoms of depression (e.g. Treadway et
al. 2012), there is increasing focus on treatments that effectively improve these symptoms. The
current work stands to support the use of drugs that specifically target DA, either through
blocking uptake (bupropion), preventing breakdown (deprenyl) or through indirect modulation
with transmitters systems that interact with DA (e.g., A2A antagonism). In each case, these
compounds were capable of reversing the effort-related impairments induced by DA depletion
via TBZ. Moreover, the DA uptake inhibitor was capable of improving performance in low
responders on the PROG/Chow task, nearly bringing them up to control levels. These findings
are supported by previous animal studies demonstrating the ability of bupropion or adenosine
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A2A antagonists to reverse the effects of TBZ (Nunes et al., submitted). Furthermore, these
findings are consistent with the human clinical literature on bupropion demonstrating that
patients treated with bupropion show marked improvements in psychomotor indices (Pae et al.
2007). Moreover, the effects of bupropion on effort-related behavioral paradigms are consistent
with the DA-related neurochemical effects measured by both microdialysis and DARPP-32 in
chapter 5.
Finally, neurochemical markers such as DARPP-32 have become a useful tool for better
understanding the effects of different manipulations on neurotransmission. These types of
analyses afford the opportunity to assess neurochemical changes at specific time points,
following specific behaviors, or following drug administration without invasive surgical
procedures. Moreover, they can potentially provide neural correlates of individual differences
seen in behavior, as in chapter 2.
Because of the potential importance of DARPP-32 expression as a marker of DA
signaling, additional analyses were done to provide more information about DARPP-32 as a
behaviorally relevant measure of DA signaling. In parallel with the bupropion DARPP-32
experiments in Chapter 5, several groups of animals across multiple conditions were sacrificed,
and their brains were analyzed using the same DARPP-32 immunofluorescence methods used in
Chapter 5. Conducting a meta-analysis, we pooled all the data from the pharmacology and
behavioral conditions, and examined differences in pDARPP-32(Thr34) within the nucleus
accumbens core from animals across a wide array of conditions (Figure 6.1). These groups range
from completely untrained, drug naïve rats to extensively trained rats with several weeks of drug
experience. Importantly, DARPP-32 expression appears to differ across these groups, and
showed evidence of both task-stimulated changes in DA transmission (consistent with Segovia et
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al., 2012) and drug-stimulated changes in DA transmission (consistent with Santerre et al., 2012;
Nunes et al., submitted). For example, the PROG drug naïve animals, who were tested on the
PROG/chow feeding choice procedure prior to the immunocytochemistry being conducted,
showed higher levels of pDARPP-32(Thr34) expression than control rats who were not
behavioral tested, but lower levels of expression than the rats that received 40.0 mg/kg
bupropion. In addition, rats that were drug naïve and behaviorally tested showed higher
pDARPP-32(Thr34) expression than rats that were behaviorally tested on the PROG/chow task,
but had previous drug experience. This suggests that previous drug experience, even several
weeks before, could alter the task-stimulated expression of pDARPP-32(Thr34). These results
provide useful information that will guide future behavioral and pharmacology experiments
involving DARPP-32 expression.
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Figure 6.1: Meta-analysis of DARPP32 expression across experiences. Mean (+SEM) DARPP32(Thr34) positive cells in NAc core. ANOVA revealed a significant effect of group on Thr34
expression in nucleus accumbens core (F[7,73] = 15.947, p < 0.05). All of these animals were
processed using the same procedure outlined in chapter 5. Previously Trained: These rats were
extensively handled and trained on the FR5/chow task or T-MAZE barrier task as part of other
experiments, but were not run on the day of tissue processing. Untrained-Untreated: These rats
received minor handling, but otherwise no treatment or training prior to tissue processing.
Untrained-VEH: These rats received no training, but were injected with saline vehicle 2 hours
prior to tissue processing to mimic bupropion operant conditions. PROG-Previous BUP
experience: These rats were from the bupropion dose response curve in chapter 5. They received
an injection of saline 30 minutes prior to a PROG/chow session, followed by tissue processing.
PROG – Previous Drug Experience: These rats were from the deprenyl and tolcapone reversal
studies in chapter 3. They ran a normal PROG/chow session and the tissue was processed
afterword. PROG – Drug Naïve: These were the control group from the Flinders Experiments in
chapter 4. They ran a normal PROG/chow session and were processed afterword. Untrained –
BUP 20: These rats received no training but were injected with 20.0 mg/kg bupropion (Chapter
5), 2 hours prior to tissue processing to mimic bupropion operant conditions. Untrained – BUP
40: These rats received no training but were injected with 40.0 mg/kg (Chapter 5), 2 hours prior
to tissue processing to mimic bupropion operant conditions. (* different from previously trained,
untrained untreated, untrained -VEH, PROG-Previous BUP experience, and PROG- Previous
Drug Experience; # different from all groups except 20.0 mg/kg bupropion)
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